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Prior presentation of findings 
The main conclusions were presented by Adam Geraghty at the Society for Academic Primary Care 
Annual Scientific Meeting, London, UK, on Wednesday July 11th 2018, as part of a 10-minute oral 
presentation called 'REDUCE programme to help people withdraw from inappropriate long-term 
antidepressant treatment'. 
 
They will also be presented by Tony Kendrick at the National Institute for Health Research School for 
Primary Care Research showcase conference in London, UK, on Tuesday 13th November, as part of a 
15-minute plenary presentation called 'REDUCE programme to help people withdraw from 
inappropriate long-term antidepressant treatment'. 
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Abstract 
Purpose 
To determine the effectiveness of interventions to manage antidepressant discontinuation, and 
outcomes for patients. 
Methods 
Systematic review with narrative synthesis and meta-analysis. Sources: MEDLINE, PubMed, Embase, 
PsycINFO, AMED, Health Management Information Consortium (HMIC), OpenGrey, and WHO 
International Clinical Trials Registry Platform (ICTRP) to March 2017. Including: randomised 
controlled trials (RCTs), quasi-experimental, and observational studies assessing interventions to 
facilitate discontinuation of antidepressants for depression in adults. Primary outcomes: 
antidepressant discontinuation, and discontinuation symptoms. Secondary outcomes: 
relapse/recurrence, quality of life, antidepressant reduction, sexual, social, and occupational 
function.  
Results 
Of 15 studies included, 12 were in the synthesis (8 RCTs, 2 single-arm trials, 2 retrospective cohort 
studies). None of the studies was rated high risk for selection or detection bias. Two studies 
prompting primary care provider (PCP) discontinuation with antidepressant tapering guidance found 
6% and 7% of patients discontinued, versus 8% for usual care. Six studies of psychological or 
psychiatric treatment plus tapering reported cessation rates of between 40% and 95%. Two studies 
reported a higher risk of discontinuation symptoms with abrupt termination.  At 2 years, risk of 
relapse/recurrence was lower with cognitive behaviour therapy (CBT) plus taper versus clinical 
management plus taper (15%-25% vs 35%-80%: RR 0.34, 95% CI 0.18 to 0.67; 2 studies). 
Relapse/recurrence rates were similar for mindfulness based cognitive therapy (MBCT) with tapering 
and maintenance antidepressants (44%-48% vs 47%-60%; 2 studies).  
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Conclusions 
CBT or MBCT can help patients discontinue antidepressants without increasing the risks of 
relapse/recurrence, but are resource intensive. More scalable interventions are needed, 
incorporating psychological support. 
(Word count 250) 
 
Introduction 
In Western countries, antidepressant prescriptions are rising steadily, doubling over 10 years.1-3 The 
main reason is increasing long-term use,4,5 with a median duration greater than five years in the 
USA,2 mostly prescribed by PCPs.2,5 While some people need antidepressants to prevent 
relapse/recurrence, 30 to 50% of long-term users have no evidence-based indication to continue.6-8 
This exposes them to potentially serious side-effects,9,10 and is costly.11  
 
However, stopping antidepressants is frequently associated with withdrawal symptoms, which can 
be problematic, and mistaken for relapse/recurrence.12 To minimise them, the American Psychiatric 
Association, and National Institute for Health and Care Excellence advise tapering doses over some 
weeks in most cases.13,14 Psychological interventions like cognitive-behaviour therapy (CBT) and 
mindfulness-based cognitive therapy (MBCT) are potential alternatives to antidepressants in 
preventing relapse/recurrence.15-17 
 
Current guidelines for antidepressant discontinuation are based on consensus, and non-systematic 
reviews have identified a need for more controlled data.18 There have been two systematic reviews 
focussing on the incidence of withdrawal symptoms after discontinuation.12,19 We conducted a 
systematic review to address two questions: what interventions are effective in managing 
antidepressant discontinuation, and what are the outcomes for patients following discontinuation? 
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Methods 
The protocol was registered with the International Prospective Register of Systematic Reviews 
(PROSPERO) in 2017, reference CRD42017072702.  
 
We included primary studies that:  
(1) concerned patients aged ≥ 18 years receiving antidepressants except mono-amine oxidase 
inhibitors (MAOI)s (usually prescribed by specialists15), for treatment of a first or recurrent episode 
of depression (defined by study authors), regardless of duration of use, or level of care (primary, 
secondary, tertiary) received. We included studies including patients with anxiety disorders, where 
>50% had depression, or mixed anxiety and depression;  
(2) assessed interventions to facilitate discontinuation of antidepressants including guided review of 
patients by PCPs, abrupt discontinuation, tapering, psychological therapies, and pharmacological 
approaches (e.g. switching to liquid fluoxetine during tapering);  
(3) had, when present, a comparator of continuation of antidepressant, alternative discontinuation 
procedure, usual care, or clinical management, but not placebo;  
(4) were: randomised controlled trials (RCTs), cluster RCTs, quasi-experimental (non-randomised 
studies, before and after studies), or observational studies.  
 
Our a priori primary outcomes were:  
 Discontinuation of antidepressants (cessation by the end of the study period) 
 Discontinuation symptoms (either measured on the discontinuation emergent signs and 
symptoms scale (DESS) or other scale,20 or listed).  
A priori secondary outcomes were:  
6 
 
 Relapse/recurrence (defined by study authors): either within six months, or more than six 
months following discontinuation  
 Quality of life  
 Antidepressant reduction  
 Sexual function 
 Other outcomes (e.g. social and occupational function, wellbeing, quality of relationships) 
 
We used the term ‘relapse/recurrence’ to include both relapse, defined through consensus as the 
return of syndrome-level depression following remission during the first 4-6 months of treatment, 
and recurrence, defined as a new episode following recovery lasting more than 4-6 months.21  This 
was because we did not specify a minimum duration of treatment prior to discontinuation, and 
patients included could have been in remission or recovery. 
 
We excluded studies that:  
(1) included patients with bipolar disorder or dementia, unless data were reported separately; 
(2) concerned treatment interruption only 
(3) were placebo-controlled trials aimed only at testing maintenance antidepressants in preventing 
relapse/recurrence. 
 
We searched the following databases from inception until March 2017: MEDLINE (Ovid), PubMed, 
Embase (Ovid), PsycINFO (EBSCOhost), AMED (EBSCOhost), HMIC, OpenGrey, and WHO ICTRP. We 
searched citations and reference lists for full papers meeting inclusion criteria from initial searches, 
and contacted pharmaceutical companies and experts.  
 
The MEDLINE search strategy was developed with an experienced health librarian (SD). It included 
subject headings/text words related to antidepressants, depression, discontinuation, and study 
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design, and was peer reviewed by three medical librarians. This strategy was then adapted by EM for 
the remaining databases, except the WHO ICTRP for which keyword combinations were used 
(Appendix 1).  
 
EM screened all titles and abstracts against inclusion criteria and TK screened a 10% sample. We 
obtained full papers where titles/abstracts met the inclusion criteria, or where there was 
uncertainty. EM and TK independently assessed whether full papers met inclusion criteria. 
Disagreements were resolved by discussion.  
 
Data extraction was performed in a standardised pre-piloted form by EM and was all checked by TK. 
It included: patient characteristics (e.g. age, sex, duration of antidepressant use); how withdrawal 
effects were ascertained; whether relapse/recurrence was distinguished from withdrawal; and 
elements of the Template for Intervention and Replication (TIDieR) checklist.22 This included 
physical/informational intervention materials, who delivered it (e.g. PCP, pharmacist, mental health 
practitioner), and how, where and when it was delivered.  
 
Risk of bias assessment was performed by EM and checked by TK. We used the Cochrane Risk of Bias 
tool,23 in accordance with the Cochrane Handbook.24 For observational studies and single arm trials 
we used the National Heart Lung and Blood Institute and Research Triangle Institute International 
tools.25 
 
Narrative and tabular summaries of key study characteristics, quality assessment and results were 
undertaken. For each outcome we presented results by study design, separately for studies of 
patients with depression only, and with mixed depression and anxiety. Where appropriate, based on 
clinical and statistical heterogeneity, data were combined in meta-analyses. For binary outcomes we 
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calculated risk ratios, and for continuous outcomes mean differences, with 95% confidence intervals 
(CIs) using a priori specified random effects models. Statistical heterogeneity was tested using the 
Chi2 test (p<0.1) and I2 statistic (I2≥50%).  
 
The meaning of our results was discussed with three patient colleagues providing Patient and Public 
Involvement input to our team. 
 
Results 
The search yielded 4996 records in total, 4694 unique (Figure 1). Of these, 4581 were ineligible after 
title and abstract review, with 99% agreement in the 10% sample screened by TK. Of the remaining 
113, 78 were excluded after assessment of full papers (see table A, appendix 2 for excluded studies). 
Thirty five papers,15-17,26-57 reporting 15 studies were therefore included.15-17,26,27,32,34,38,42,50,51,53-55,57 Of 
these 15, one was published as an abstract only.26  
 
Table B, Appendix 2 shows study characteristics. Twelve were completed,15-17,27,32,34,38,42,50,51,53,54 and 
included in our synthesis. Two were ongoing (both RCTs, one of tapering for two weeks versus one 
week,57 and one of guided tapering plus CBT versus maintenance antidepressants in pregnant 
women.)55,56 
 
Eight of the completed studies were RCTs (one cluster RCT27 and one34 with only one relevant study 
arm),15-17,27,32,34,38,42 two single arm trials,50,51 and two retrospective cohort studies.53,54 Numbers of 
patients ranged from 12 to 2849.50,51 Seven included participants with depression and/or anxiety 
disorder,15-17,27,32,50,53 and five depression only.34,38,42,51,54 Criteria used for depression were reported 
in nine, including the Diagnostic and Statistical Manual (DSM-IV) (7)16,17,34,38,42,53,54 and Research 
Diagnostic Criteria (RDC) (2),15,32  (Table B). 
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Twelve named the antidepressants being discontinued. Two concerned discontinuation of a single 
antidepressant (desvenlafaxine,38 and paroxetine54), one tricyclic antidepressant (TCA) and related 
antidepressants,15 one newer antidepressants,51 one predominantly SSRIs,42 and seven both older 
and newer.16,17,27,32,34,50,53 Inclusion criteria for duration of use were reported in eight and included ≥4 
weeks (1),51 24 weeks (1),38 3 to 5 months (1),15 ≥6 months (3),16,34,42 ≥9 months (1), 27 and ≥ 2 
years.,50  Mean/median length of antidepressant use was reported in three,24,50,54 ranging from 9.2 
months54  to 9.5 years.27  Inclusion criteria for length of remission/recovery were reported in 
four,32,34,42,51 ranging from 8 weeks42 to six months51.  Three studies of MBCT included a significant 
proportion of patients in partial remission16,17,34 (Table B). 
 
Interventions included: patient specific letter to the PCP with recommendation to discontinue 
antidepressant and tapering advice;27 prompted PCP review of condition and medication;50 CBT with 
tapering;15,32,42,51 MBCT with tapering;16,17,34 gradual discontinuation;53,54 and one week tapering.38 
Comparators included: maintenance antidepressant treatment; rapid discontinuation; abrupt 
discontinuation; clinical management plus taper; and usual care (Table B). Apart from sexual 
function, data were reported for all pre-specified outcomes of interest. 
 
For RCTs, no included study was rated high risk for selection or detection bias. Performance bias was 
rated either high risk due to the nature of interventions, or unclear (Table C, Appendix 2). Single arm 
trials had clearly defined, valid, reliable, and consistently implemented outcome measures, and for 
both observational studies, timeframes were sufficient to see associations between exposure and 
outcomes (Table D, Appendix 2). 
 
Discontinuation of antidepressants  
Eight studies (six RCTs, two single arm) reported on discontinuation (Table 1).15-17,27,32,34,42,50  
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Timepoints ranged from post-intervention to 24 months from baseline, and cessation rates from 6% 
to 95%. The lowest rate occurred with patient-specific letters to PCPs recommending antidepressant 
discontinuation, with tapering advice.27 There was no significant difference in cessation between this 
(6%) and usual care (8%) after 12 months (relative risk (RR) 0.75, 95% CI 0.22 to 2.53). Patients who 
discontinued tended to have a shorter duration of use. 
 
The highest cessation rates (87% and 95%) were in two studies comparing CBT plus tapering to 
clinical management plus tapering, delivered by the same psychiatrist.15,32 When results from these 
were combined in meta-analysis, there was no significant difference in discontinuation after 20 
weeks (RR 1.01, 95% CI 0.89 to 1.15; Chi2 = 0.49, I2 = 0%). Cessation rates in three studies of MBCT 
with tapering support ranged from 55% to 75%.16,17,34 
 
Antidepressant discontinuation symptoms  
One RCT and one retrospective cohort reported on discontinuation symptoms (Table 2).38,54  One 
compared abrupt discontinuation of desvenlafaxine 50 mg/day versus tapering using 25 mg/day for 
one week.38 There was significantly lower risk of discontinuation emergent adverse events with one 
week taper versus abrupt discontinuation (RR 0.76, 95% CI 0.58 to 0.98).38 There was no statistically 
significant difference in the risk of discontinuation syndrome. However, the study may have been 
underpowered to detect a difference, with 140 patients in the tapering, and 148 in the abrupt 
discontinuation arm.38  
 
In a study of clinical records of 385 patients treated with paroxetine for a single episode of major 
depressive disorder,54 discontinuation syndrome occurred significantly more frequently in patients 
who discontinued abruptly (66% of patients reporting discontinuation syndrome compared with 15% 
of patients not reporting it; RR 7.35, 95% CI 4.05 to 13.35). Patients experiencing discontinuation 
syndrome were significantly younger (p = 0.016), but more young patients discontinued abruptly. Of 
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41 patients experiencing discontinuation syndrome, 36 were re-administered paroxetine and 
subsequently tapered off at 5mg every 2–4 weeks, with no recurrence of discontinuation syndrome. 
However, as 10mg tablets were the only form available, patients had to divide them.  
 
Relapse/recurrence within six months  
Three studies (one single arm, two retrospective cohorts) reported relapse/recurrence within six 
months of discontinuation (Table E, Appendix 2).51,53,54 In both cohort studies, attempts were made 
to differentiate discontinuation symptoms from relapse/recurrence: e.g. in one, inclusion criteria 
stated patients had to remain euthymic for one week after discontinuation.53 
 
One small (n=12), feasibility study of CBT for preventing recurrence in women who wished to 
discontinue before pregnancy, found two whose depression recurred within 10 weeks of tapering.51  
In a retrospective cohort study, of 41 patients who experienced discontinuation syndrome after 
stopping paroxetine, none had recurrence following subsequent slower titration (88%) or switch of 
antidepressants (12%).54  In a second cohort, median time to recurrence of depressive or panic 
disorder was more than twice as long after gradual versus rapid discontinuation.53  Newer 
antidepressants (SSRIs, bupropion, duloxetine, venlafaxine) were associated with a shorter time to 
recurrence than TCAs/tetracyclics.53 
 
Recurrence after more than six months  
Six studies reported late recurrence (Table F, Appendix 2)15-17,27,32,34 at time points ranging from 12 
months to six years after discontinuation. In one, a score of 5 for two weeks on the Structured 
Clinical Interview for Depression Longitudinal Interval Follow-up Evaluation (SCID-LIFE) could have 
included patients experiencing withdrawal affecting mood temporarily, overestimating recurrence.18  
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There was no significant difference in recurrence following patient-specific recommendations to 
PCPs to discontinue plus tapering guidance, compared to usual care (26% vs 13%: RR 1.95, 95% CI 
0.97 to 3.94).27  Meta-analysis of two CBT studies15,32 showed significantly lower risks of recurrence 
with CBT plus taper compared to clinical management plus taper after two years (15%-25% vs 35%-
80%: RR 0.34, 95% CI 0.18 to 0.67; Chi2=0.19, I2=0%), and six years (40%-50% vs 75%-90%: RR 0.55, 
95% CI 0.37 to 0.82; Chi2=1.12, I2=11%).  Meta-analysis of two MBCT studies showed no difference in 
recurrence between MBCT with tapering support and maintenance antidepressants at ≥15 months 
(44%-48% vs 47%-60%: RR 0.90, 95% CI 0.75 to 1.07; Chi2=0.68, I2=0%).16,17 The recurrence rate at 15 
months was similar (54%) in another study providing MBCT with tapering support in one arm.34  
 
Quality of Life 
Four studies (three RCTs, one single arm trial) reported on quality of life (Table G, Appendix 
2).16,17,27,51 In one there was no significant effect on quality adjusted life years. 27 Meta-analysis was 
possible for two comparing MBCT with tapering versus maintenance antidepressants.16,17 These 
meta-analyses found no significant difference on the physical domain of the WHO Quality of Life 
instrument (WHOQOL-BREF), but a statistically significant difference favouring MBCT with tapering 
support in the psychological and social domains after 1 month; at ≥ 12 months there was no 
statistically significant difference for all three domains. In one study there was no statistically 
significant difference in European Quality of Life five dimensions questionnaire (EQ-5D) scores 
between MBCT with tapering support and maintenance antidepressants at any assessed 
timepoints.17   
 
In one single arm CBT study, quality of life scores for participants who did not relapse (9 out of 12), 
decreased after 16 weeks acute treatment but improved again at 24 weeks after booster 
treatment.51  
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Reduction in antidepressant use  
Four studies reported reduction in antidepressant use (Table H, Appendix 2).17,34,42,50 Reduction rates 
ranged from 13% of patients for PCP review, to 19% with minimum 50% reduction in use following 
CBT plus tapering.50,42 
 
Discussion  
Summary of main findings 
We found discontinuation rates varied from only 6%-7% for prompted PCP patient review and 
guided tapering, to 40%-95% for specialist psychological or psychiatric interventions. Only two 
studies reported on discontinuation symptoms. One RCT38 found a lower risk of serious adverse 
events with one week taper versus abrupt discontinuation of desvenlafaxine, whilst a retrospective 
cohort study54 found discontinuation syndrome significantly more common after abrupt paroxetine 
cessation.   
 
Rates of relapse/recurrence were low in primary care (13%-26%) compared to psychiatric or 
psychological therapy settings (15%-90%), presumably related to the larger proportion of patients 
with multiple recurrences and/or partial remission on antidepressants in specialist settings, but 
there has been very little research in primary care.  A primary care placebo-controlled trial of 
maintenance SSRI treatment to prevent depression recurrence (excluded from this review) found 
similar rates, of 10% in the continuation arm and 23% in the taper arm over 18 months.58 
 
The risk of relapse/recurrence was significantly reduced by combining cognitive behaviour therapy 
(CBT) with tapering versus clinical management and tapering alone. Mindfulness based cognitive 
therapy with tapering enabled high rates of discontinuation without increasing relapse/recurrence 
rates, compared to maintenance antidepressants. 
14 
 
 
Strengths and limitations  
We conducted a sensitive search across several databases, including grey literature, unrestricted by 
date, language or publication status, to minimise publication and language bias. One researcher 
performed study selection, data extraction and risk of bias assessment, with extracted data and bias 
assessments carefully checked by another experienced reviewer. This is time-efficient but may incur 
more errors than double data extraction.59 
 
Comparison with the literature 
Our findings tend to support consensus guidance that antidepressants should be tapered rather than 
discontinued abruptly, but there is a need for more trials, of slower tapering.18  One ongoing study is 
comparing one-week with two-week tapering.57  Our findings are consistent with short-term drug 
interruption studies (also excluded from this review) showing that discontinuation syndrome occurs 
more often on abrupt cessation of paroxetine, presumably due to its short half-life.60, 61  
 
Discontinuation took place in some studies during ‘continuation’ treatment to prevent relapse 
within 4-6 months of remission, and in others during ‘maintenance’ treatment to prevent 
recurrence.62  This is a potentially important distinction, because guidelines recommend 6-9 months 
continuation treatment for a first episode of depression, and maintenance treatment for two years 
or more for recurrent episodes,13,14 although the clinical utility of this distinction was questioned by 
a systematic review which found no clear difference between continuation and maintenance 
treatment in reducing the risk of relapse/recurrence.63   
 
Implications for practice and research  
It is important for PCPs to discuss discontinuation symptoms with patients, at the time of initiation 
of an antidepressant. This will allow them to make more informed decisions about whether they 
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want to start an antidepressant in the first place.  Patients may also be reassured that relapse rates 
may be lower in the primary care setting, although more research needs to be done to confirm that.  
 
Discontinuation symptoms are probably reduced by tapering but slow tapering is a challenge given a 
lack of suitable formulations. One study found most patients could discontinue paroxetine with a 
taper of 5mg every 2–4 weeks, but patients had to break tablets in half.54  Switching to fluoxetine, 
with its longer half-life and availability in liquid form, may enable successful slow tapering,18 but this 
does not appear to have been subject to a trial.  
 
Discontinuation symptoms may affect patients’ willingness to stop antidepressants and be 
confounded with relapse/recurrence, so future studies should distinguish between them. They 
should also distinguish between discontinuing continuation and maintenance antidepressant 
treatment.   
 
Providing psychological therapies seems to enable significantly greater discontinuation rates than 
brief guidance on tapering to PCPs alone. The mechanism could be through providing support to  
patients to manage fears of withdrawal, relapse and lack of self-efficacy, which are possible barriers 
to discontinuation.64  However, it could also be that having an effective therapy for 
depression/anxiety for which the medication was initially given removes the need for it,  
without increasing the risk of relapse/recurrence.  Access to face-to-face CBT or MBCT is likely to be 
quite limited however, warranting the exploration of psychologically-informed digital support for 
discontinuation to complement PCP care, given the high prevalence of people on potentially 
inappropriate long-term antidepressant treatment.  
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Table 1: Studies reporting successful discontinuation of antidepressants 
Study (design) Time point –  
from baseline 
Intervention 
(cessation rate) 
Comparator 
(cessation rate) 
Risk ratio (95% CI) 
Depression (exclusion or non-reporting of anxiety comorbidities) 
Klein 201742 
(RCT)1 
6 months CBT+ taper 
(34/85 = 40%) 
 
m-ADM (n/a) n/a 
Huijbers 201634  
(Single arm from RCT) 2 
6 months; 
after 6 months 
MBCT-TS 
(68/128 = 53%; 
70/128 = 55%) 
 
n/a n/a 
Depression and/or anxiety disorders 
Eveleigh 201527 
(RCT) 3 
12 months Letter to PCP with 
recommendation 
+ tapering advice 
(4/67 = 6%) 
 
Usual care 
(6/75 = 8%) 
0.75 (0.22 to 2.53); 
1 study 
 
 
 
Fava 199415  
(RCT) 
20 weeks CBT + taper 
(20/21 = 95%) 
 
CM + taper 
(20/22 = 91%) 
1.01 (0.89 to 1.15; 
I2 = 0%); 2 studies 
 
Fava 199832 
(RCT) 
20 weeks CBT + taper 
(20/23 = 87%) 
 
CM + taper 
(20/22 = 91%) 
Kuyken 200816 
(RCT) 3 
6 months MBCT-TS 
(46/61 = 75%) 
 
m-ADM 
(n/a) 
n/a 
Kuyken 201517 
(RCT) 4 
24 months MBCT-TS 
(124/176 = 70%) 
 
m-ADM 
(n/a) 
n/a 
Johnson 201250 
(single arm) 
Post-intervention Guided PCP 
review 
(199/2849 = 7%) 
 
n/a n/a 
1 3 arm RCT, but only 2 arms are relevant for this review, ITT analysis; 2 2 arm RCT but only 1 arm is relevant for this review 
(second arm: MBCT + m-ADM); ITT analysis 3 ITT analysis; 4 per protocol analysis (completed 4 sessions of MBCT, 83% of 
those randomised to intervention arm) 
CM clinical management; CBT cognitive behavioural therapy; m-ADM maintenance antidepressant medication; MBCT-TS 
Mindfulness based cognitive therapy with support to taper; n/a not applicable; PCP Primary Care Provider 
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Table 2: Studies reporting antidepressant discontinuation symptoms 
 
Study (design) Time point  
 
Intervention 
(event rate) 
Comparator 
(event rate) 
Risk ratio (95% CI) 
Depression (exclusion or non-reporting of anxiety comorbidities) 
Khan 201438  
(RCT)  
Incidence of 
taper/post-therapy 
emergent adverse 
event1 
 
Double-blind 
phase: Baseline 
(Study Day 168) 
up to Week 4 
1 week taper 
(54/139=39%) 
Abrupt 
discontinuation 
(75/146=51% ) 
0.76 (0.58 to 0.98); 
1 study 
 
Proportion of patients 
with discontinuation 
syndrome2 
 
 
Double-blind 
phase: Baseline 
(Study Day 168) 
up to Week 4 
1 week taper 
(30/139=22%) 
 
Abrupt 
discontinuation 
(31/146= 21%) 
1.02 (0.65 to 1.59); 
 1 study 
 
Himei 200654 
(Retrospective cohort) 
Patients with discontinuation syndrome (n=41, abrupt 
(n=27) or gradual (n=14) withdrawal of paroxetine (10mg 
reduction every 2 weeks)) 3 compared to patients with 
non-discontinuation syndrome (n=344, abrupt (n=53) or 
gradual (n=291) withdrawal of paroxetine) 
7.35 (4.05 to 
13.35); 1 study 
 
1 adverse events that started or increased in severity during the double blind phase; 2 an increase of 4 or more points in 
DESS between baseline and mean score during the first 2 weeks of the double blind phase; 3 diagnosis in medical records, 
and reconfirmation of diagnosis according to the criteria for the SSRI discontinuation syndrome proposed by Black et al., 
2000 (i.e.: (i) the symptoms of the discontinuation syndrome appear within 3 days following cessation/ reduction in the 
dosage of paroxetine; (ii) two or more of the following symptoms are present: dizziness, light-headedness, headache, 
nausea, paraesthesia, loss of balance, irritability, agitation and insomnia; (iii) the symptoms cannot be explained as a 
relapse of depression or as any other medical condition; and (iv) the symptoms cause significant distress or impairment in 
social, occupational and other important areas of functioning). 
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FIGURES 
 
Figure 1: Flowchart of study selection 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Records identified through database 
searching 
(n = 4996) 
Additional records identified through 
other sources 
(n = 18) 
Records after duplicates removed 
(n = 4694) 
Records screened 
(n = 4694) 
Records excluded 
(n = 4581) 
Full-text articles assessed for 
eligibility 
(n = 113) 
Full-text articles excluded,  
(n = 78) 
Studies included in Review 
(n = 15; 35 papers) 
Studies included in synthesis  
(n=14) 
APPENDIX 1 - SEARCH STRATEGIES 
MEDLINE 
Ovid MEDLINE(R) Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) 
Daily and Ovid MEDLINE(R) 1946 to 23 March 2017 
Search 
ID# 
Query Items 
found 
1 exp ANTIDEPRESSIVE AGENTS/ 133782 
2 exp NEUROTRANSMITTER UPTAKE INHIBITORS/ 133192 
3 (psychotropic* or antidepress* or anti depress* or ((serotonin or norepinephrine or 
noradrenaline or nor epinephrine or nor adrenaline or neurotransmitt* or dopamine*) 
and (uptake or reuptake or re-uptake)) or noradrenerg* or antiadrenergic or anti 
adrenergic or SSRI* or SNRI* or TCA* or tricyclic* or tetracyclic* or 
heterocyclic*).ti,kf,hw. 
136112 
4 (Agomelatine or Alaproclate or Alnespirone or Amoxapine or Amersergide or 
Amfebutamone or Amiflamine or Amineptine or Amitriptylin* or Amitriptylinoxide or 
Amoxapine or Aripiprazole or Atomoxetine or Tomoxetine or Befloxatone or Benactyzine 
or Binospirone or Brofaromine or Bupropion or Butriptylin*or Caroxazone or Chlopoxiten 
or Cianopramine or Cilobamine or Cilosamine or Cimoxatone or Citalopram or 
(Chlorimipramin* or Clomipramin* or Chlomipramin* or Clorimipramine) or Clorgyline or 
Clovoxamine or Dapoxetine or Deanol or Dibenzepin or Demexiptilin* or Deprenyl or 
Desipramine or Desvenlafaxine or Dibenzepin or Diclofensin* or Dimetacrin* or 
(Dosulepin or Dothiepin) or Doxepin or Duloxetine or DVS 233 or Enilospirone or 
Eptapirone or Escitalopram or Etoperidone or Femoxetine or Fenfluramin* or Fluotracen 
or Fluoxetine or Fluparoxan or Furazolidone or Fluvoxamine).ti,kf,hw. 
44215 
5 (Harmaline or Harmine or Hyperforin or Hypericum or John* Wort or Idazoxan or 
Imipramin* or Iprindole or Iproniazid* or Ipsapirone or Imipraminoxide or 
Isocarboxazid*or Lesopitron or Levomilnacipran or Lithium or Lofepramin* or (Lu 
AA21004 or Vortioxetine) or Lu AA24530 or LY2216684 or Maprotiline or Medifoxamine 
or Melitracen or Metapramine or Methylphenidate or Mianserin or Milnacipran or 
Minaprine or Mirtazapine or Moclobemide or Monocrotophos or Nefazodone or 
Nialamide or Nitroxazepine or Nomifensine or Norfenfluramine or Nortriptyline or 
Noxiptilin*).ti,kf,hw. 
67830 
6 (Opipramol or Oxaflozane or Paroxetine or Phenelzine or Pheniprazine or Pipofezin* or 
Pirandamine or Piribedil or Pirlindole or Pivagabine or Pizotyline or Propizepine or 
(Protriptylin* or Pertofrane) or Quinupramine or Quipazine or Reboxetine or Ritanserin 
or Rolipram or Scopolamine or Selegiline or Sertraline or (Setiptiline or Teciptiline) or 
Tandospirone or Teniloxine or Tetrindole or Thiazesim or Thozalinone or Tianeptin* or 
Toloxatone or Tranylcypromine or Trazodone or Trimipramine or 5 Hydroxytryptophan or 
5 HT or Tryptophan or Hydroxytryptophan or Venlafaxine or Viloxazine or Vilazodone or 
Viqualine or Zalospirone or Zimeldine).ti,kf,hw. 
72802 
7 1 or 2 or 3 or 4 or 5 or 6 328279 
8 MOOD DISORDERS/ or DEPRESSIVE DISORDER/ or DEPRESSION, POSTPARTUM/ or 
DEPRESSIVE DISORDER, MAJOR/ or DEPRESSIVE DISORDER, TREATMENT-RESISTANT/ 
106670 
9 DEPRESSION/ 95781 
10 ADJUSTMENT DISORDERS/ 4180 
11 (mixed anxiety adj2 depression).ti,ab,kf. 222 
12 (mixed anxiety adj2 depressive disorder).ti,ab,kf. 85 
13 8 or 9 or 10 or 11 or 12 195538 
14 (cease or cessation* or discontinu* or interrupt or interruption or taper* or reduce or 
drug holiday or post withdraw* or postwithdraw* or (stop* adj (taking or using)) or 
909991 
withdraw* or terminat* or deprescrib* or de prescrib* or deprescrip* or de 
prescrip*).ti,ab,kf. 
15 (prevent* adj3 relaps*).ti,ab,kf. 8318 
16 (prevent* adj3 recurr*).ti,ab,kf. 17925 
17 SECONDARY PREVENTION/ 17455 
18 14 or 15 or 16 or 17 943451 
19 controlled clinical trial.pt. 93357 
20 randomized controlled trial.pt. 456910 
21 (randomi#ed or randomi#ation).ti,ab. 516857 
22 randomly.ab. 276324 
23 trial.ti,ab. 487920 
24 groups.ab. 1701672 
25 (control* adj3 (trial* or study or studies)).ti,ab. 422582 
26 RANDOMIZED CONTROLLED TRIAL/ or PRAGMATIC TRIAL/ 457032 
27 (quasi adj (experimental or random$)).ti,ab. 12796 
28 ((waitlist* or wait* list* or treatment as usual or TAU) adj3 (control or group)).ab. 4446 
29 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 2645649 
30 EPIDEMIOLOGIC STUDIES/ 7454 
31 exp CASE CONTROL STUDIES/ 850134 
32 exp COHORT STUDIES/ 1651640 
33 Case control.tw. 101281 
34 (cohort adj (study or studies)).tw. 135409 
35 Cohort analy$.tw. 5537 
36 (Follow up adj (study or studies)).tw. 43887 
37 (observational adj (study or studies)).tw. 71418 
38 Longitudinal.tw. 189339 
39 Retrospective.tw. 387610 
40 Cross sectional.tw. 249383 
41 CROSS-SECTIONAL STUDIES/ 239537 
42 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 2415411 
43 Case series.tw. 53257 
44 CASE REPORT/ 1866965 
45 Case* report*.tw. 316198 
46 case* stud*.tw. 78415 
47 43 or 44 or 45 or 46 2061422 
48 29 or 42 or 47 6302954 
49 7 and 13 and 18 and 48 2967 
50 remove duplicates from 49 2802 
51 (rodent* or rat or rats or mouse or mice or animal model*).ti. 1271813 
52 (smoking or tobacco or nicotine).ti. or smoking cessation.mp. 109483 
53 (antibiotic* or antimicrob* or antifung* or statin*).ti. 155057 
54 (comment or editorial or meta-analysis or practice-guideline or review).pt. 3279247 
55 51 or 52 or 53 or 54 4744048 
56 50 not 55 2212 
 
PubMed 
PubMed, inception to 23 March 2017 
Search 
ID# 
Query Items 
found 
#53 Search (#47 NOT #52) 1162 
#52 Search (#48 OR #49 OR #50 OR #51) 4216683 
#51 Search (((Editorial[PT] or Guideline[PT] or Meta-Analysis[PT] or Review[PT]))) 2690893 
#50 Search ((((antibiotic*[TI] or antimicrob*[TI] or antifung*[TI] or statin*[TI])))) 152759 
#49 Search ((((smoking[TI] or tobacco[TI] or nicotine[TI]) or smoking cessation[ALL]))) 108342 
#48 Search ((((rodent*[TI] or rat[TI] or rats[TI] or mouse[TI] or mice[TI] or animal model*[TI] or 
rabbit[TI])))) 
1326349 
#47 Search (#7 AND #12 AND #17 AND #46) 1554 
#46 Search (#29 OR #41 OR #45) 6335149 
#45 Search (#42 OR #43 OR #44) 1869485 
#44 Search Case reports [PT] 1825701 
#43 Search Case reports[MESH:NOEXP] 141 
#42 Search Case series[TIAB] 52191 
#41 Search (#30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40) 2281136 
#40 Search Cross sectional[TIAB] 243232 
#39 Search Retrospective[TIAB] 378173 
#38 Search Longitudinal[TIAB] 185722 
#37 Search (((observational study[TIAB] or observational studies[TIAB]))) 69599 
#36 Search (((Follow up study[TIAB] or follow up studies[TIAB]))) 43627 
#35 Search Cohort analy*[TIAB] 5903 
#34 Search (((cohort study[TIAB] or cohort studies[TIAB]))) 132794 
#33 Search Case control[TIAB] 99475 
#32 Search cohort studies[MESH] 1602115 
#31 Search Case-control studies[MESH] 826296 
#30 Search Epidemiologic studies[MESH:NOEXP] 7274 
#29 Search (#18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28) 2968202 
#28 Search (((waitlist*group [TIAB]or wait* list*group[TIAB] or treatment as usual group[TIAB] 
or TAU group[TIAB]))) 
582 
#27 Search ((((waitlist* control [TIAB]or wait* list*control[TIAB] or treatment as usual 
control[TIAB] or TAU control[TIAB]))) 
6811 
#26 Search (((quasi experimental[TIAB] or quasi random*[TIAB]))) 12445 
#25 Search ((RANDOMIZED CONTROLLED TRIAL[MESH:NOEXP] or PRAGMATIC CLINICAL 
TRIAL[MESH:NOEXP])) 
107877 
#24 Search (((control* trial*[TIAB] or control* study[TIAB] or control* studies[TIAB]))) 691375 
#23 Search groups[TIAB] 1688863 
#22 Search trial[TIAB] 459756 
#21 Search Randomly [TIAB] 268179 
#20 Search (((randomized[TIAB] or randomised[TIAB] or randomization[TIAB] or 
randomisation[TIAB]))) 
490603 
#19 Search randomized controlled trial [PT] 430440 
#18 Search controlled clinical trial [PT] 516899 
#17 Search (#13 OR #14 OR #15 OR #16) 296571 
#16 Search SECONDARY PREVENTION[MESH:NOEXP] 16781 
#15 Search (prevent* recur* [TIAB]) 62250 
#14 Search (prevent* relaps* [TIAB]) 21759 
#13 Search (((cease [TIAB] or cessation* [TIAB] or discontinu* [TIAB] or interrupt [TIAB] or 
interruption [TIAB] or taper*[TIAB] or reduce [TIAB] or drug holiday [TIAB] or post 
withdraw* [TIAB] or postwithdraw* [TIAB] or stop* taking [TIAB] stop* using [TIAB] or 
withdraw* [TIAB] or terminat* [TIAB] or deprescrib* [TIAB] or de prescrib* [TIAB] or 
deprescrip* [TIAB] or de prescrip* [TIAB]))) 
210433 
#12 Search (#8 OR #9 OR #10 OR #11) 189000 
#11 Search mixed anxiety [TIAB] 358 
#10 Search ADJUSTMENT DISORDERS[MESH:NOEXP] 4057 
#9 Search DEPRESSION [MESH:NOEXP] 151804 
#8 Search ((MOOD DISORDERS[MESH:NOEXP] or DEPRESSIVE DISORDER[MESH:NOEXP] or 
DEPRESSION, POSTPARTUM [MESH:NOEXP] or DEPRESSIVE DISORDER, MAJOR 
[MESH:NOEXP] or DEPRESSIVE DISORDER, TREATMENT-RESISTANT [MESH:NOEXP])) 
103027 
#7 Search (#1 OR #2 OR #3 OR #4 OR #5 OR #6) 321750 
#6 Search (((Opipramol [TIAB] or Oxaflozane [TIAB] or Paroxetine[TIAB] or Phenelzine[TIAB] 
or Pheniprazine[TIAB] or Pipofezin* [TIAB] or Pirandamine [TIAB] or Piribedil[TIAB] or 
Pirlindole[TIAB] or Pivagabine[TIAB] or Pizotyline[TIAB] or Propizepine[TIAB] or 
(Protriptylin*[TIAB] or Pertofrane[TIAB]) or Quinupramine[TIAB] or Quipazine[TIAB] or 
Reboxetine[TIAB] or Ritanserin[TIAB] or Rolipram[TIAB] or Scopolamine[TIAB] or 
Selegiline[TIAB] or Sertraline[TIAB] or (Setiptiline[TIAB] or Teciptiline[TIAB]) or 
Tandospirone[TIAB] or Teniloxine[TIAB] or Tetrindole[TIAB] or Thiazesim[TIAB] or 
Thozalinone[TIAB] or Tianeptin*[TIAB] or Toloxatone[TIAB] or Tranylcypromine[TIAB] or 
Trazodone[TIAB] or Trimipramine[TIAB] or 5 Hydroxytryptophan[TIAB] or 5 HT[TIAB] or 
Tryptophan[TIAB] or Hydroxytryptophan[TIAB] or Venlafaxine[TIAB] or Viloxazine[TIAB] or 
Vilazodone[TIAB] or Viqualine[TIAB] or Zalospirone[TIAB] or Zimeldine[TIAB]))) 
104458 
#5 Search (((Harmaline[TIAB] or Harmine[TIAB] or Hyperforin[TIAB] or Hypericum[TIAB] or 
John* Wort [TIAB] or Idazoxan[TIAB] or Imipramin*[TIAB] or Iprindole[TIAB] or 
Iproniazid*[TIAB] or Ipsapirone[TIAB] or Imipraminoxide[TIAB] or Isocarboxazid*[TIAB] or 
Lesopitron[TIAB] or Levomilnacipran[TIAB] or Lithium[TIAB] or Lofepramin*[TIAB] or (Lu 
AA21004[TIAB] or Vortioxetine[TIAB]) or Lu AA24530 [TIAB] or LY2216684[TIAB] or 
Maprotiline[TIAB] or Medifoxamine[TIAB] or Melitracen[TIAB] or Metapramine[TIAB] or 
Methylphenidate[TIAB] or Mianserin[TIAB] or Milnacipran[TIAB] or Minaprine[TIAB] or 
Mirtazapine[TIAB] or Moclobemide[TIAB] or Monocrotophos[TIAB] or Nefazodone[TIAB] 
or Nialamide[TIAB] or Nitroxazepine[TIAB] or Nomifensine[TIAB] or Norfenfluramine[TIAB] 
or Nortriptyline[TIAB] or Noxiptilin*[TIAB]))) 
68596 
#4 Search (((Agomelatine[TIAB] or Alaproclate[TIAB] or Alnespirone[TIAB] or 
Amoxapine[TIAB] or Amersergide[TIAB] or Amfebutamone[TIAB] or Amiflamine[TIAB] or 
Amineptine[TIAB] or Amitriptylin*[TIAB] or Amitriptylinoxide[TIAB] or Amoxapine[TIAB] or 
Aripiprazole [TIAB] or Atomoxetine[TIAB] or Tomoxetine[TIAB] or Befloxatone[TIAB] or 
Benactyzine[TIAB] or Binospirone[TIAB] or Brofaromine[TIAB] or Bupropion[TIAB] or 
Butriptylin*[TIAB] or Caroxazone[TIAB] or Chlopoxiten[TIAB] or Cianopramine[TIAB] or 
Cilobamine[TIAB] or Cilosamine[TIAB] or Cimoxatone[TIAB] or Citalopram[TIAB] or 
(Chlorimipramin*[TIAB] or Clomipramin*[TIAB] or Chlomipramin*[TIAB] or 
Clorimipramine[TIAB]) or Clorgyline[TIAB] or Clovoxamine[TIAB] or Dapoxetine[TIAB] or 
Deanol[TIAB] or Dibenzepin[TIAB] or Demexiptilin*[TIAB] or Deprenyl [TIAB] or 
Desipramine[TIAB] or Desvenlafaxine[TIAB] or Dibenzepin[TIAB] or Diclofensin*[TIAB] or 
Dimetacrin*[TIAB] or (Dosulepin[TIAB] or Dothiepin[TIAB]) or Doxepin[TIAB] or 
Duloxetine[TIAB] or DVS 233[TIAB] or Enilospirone [TIAB] or Eptapirone[TIAB] or 
Escitalopram[TIAB] or Etoperidone[TIAB] or Femoxetine[TIAB] or Fenfluramin*[TIAB] or 
Fluotracen [TIAB] or Fluoxetine[TIAB] or Fluparoxan[TIAB] or Furazolidone[TIAB] or 
Fluvoxamine[TIAB]))) 
46087 
#3 Search (((psychotropic*[TIAB] or antidepress*[TIAB] or anti depress*[TIAB] or 
((serotonin[TIAB] or norepinephrine[TIAB] or noradrenaline[TIAB] or nor 
epinephrine[TIAB] or nor adrenaline[TIAB] or neurotransmitt*[TIAB] or dopamine*[TIAB]) 
144261 
and (uptake[TIAB] or reuptake[TIAB] or re-uptake[TIAB])) or noradrenerg*[TIAB] or 
antiadrenergic[TIAB] or anti adrenergic[TIAB] or SSRI*[TIAB] or SNRI*[TIAB] or TCA*[TIAB] 
or tricyclic*[TIAB] or tetracyclic*[TIAB] or heterocyclic*[TIAB]))) 
#2 Search NEUROTRANSMITTER UPTAKE INHIBITORS[MESH] 25774 
#1 Search ANTIDEPRESSIVE AGENTS[MESH] 52011 
 
  
Embase 
Embase (Ovid), 1974 to 22 March 2017 
Search 
ID# 
Query Items 
found 
1 Psychopharmacology/ 27419 
2 Psychotropic Agent/ 28452 
3 exp Antidepressant Agent/ 376797 
4 Serotonin Receptor Affecting Agent/ or Serotonin Uptake Inhibitor/ or Serotonin 
Noradrenalin Reuptake Inhibitor/ or Triple Reuptake inhibitor/ 
48677 
5 Dopamine Receptor Affecting Agent/ or Dopamine Uptake Inhibitor/ 1521 
6 Adrenergic Receptor Affecting Agent/ or Noradrenalin Uptake Inhibitor/ 4222 
7 Neurotransmitter Uptake Inhibitors/ 160 
8 (antidepress* or anti depress* or ((serotonin or norepinephrine or noradrenaline or nor 
epinephrine or nor adrenaline or neurotransmitt* or dopamine*) and (uptake or reuptake 
or re-uptake)) or noradrenerg* or antiadrenergic or anti adrenergic or SSRI* or SNRI* or 
TCA* or tricyclic* or tetracyclic* or heterocyclic* or psychotropic*).mp. 
293136 
9 (Agomelatine or Alaproclate or Alnespirone or Amoxapine or Amersergide or 
Amfebutamone or Amiflamine or Amineptine or Amitriptylin* or Amitriptylinoxide or 
Amoxapine or Aripiprazole or Atomoxetine or Tomoxetine or Befloxatone or Benactyzine 
or Binospirone or Brofaromine or Bupropion or Butriptylin*or Caroxazone or Chlopoxiten 
or Cianopramine or Cilobamine or Cilosamine or Cimoxatone or Citalopram or 
(Chlorimipramin* or Clomipramin* or Chlomipramin* or Clorimipramine) or Clorgyline or 
Clovoxamine or Dapoxetine or Deanol or Dibenzepin or Demexiptilin* or Deprenyl or 
Desipramine or Desvenlafaxine or Dibenzepin or Diclofensin* or Dimetacrin* or (Dosulepin 
or Dothiepin) or Doxepin or Duloxetine or DVS 233 or Enilospirone or Eptapirone or 
Escitalopram or Etoperidone or Femoxetine or Fenfluramin* or Fluotracen or Fluoxetine or 
Fluparoxan or Furazolidone or Fluvoxamine).ti,kw,hw. 
151125 
10 (Harmaline or Harmine or Hyperforin or Hypericum or John* Wort or Idazoxan or 
Imipramin* or Iprindole or Iproniazid* or Ipsapirone or Imipraminoxide or 
Isocarboxazid*or Lesopitron or Levomilnacipran or Lithium or Lofepramin* or (Lu AA21004 
or Vortioxetine) or Lu AA24530 or LY2216684 or Maprotiline or Medifoxamine or 
Melitracen or Metapramine or Methylphenidate or Mianserin or Milnacipran or Minaprine 
or Mirtazapine or Moclobemide or Monocrotophos or Nefazodone or Nialamide or 
Nitroxazepine or Nomifensine or Norfenfluramine or Nortriptyline or Noxiptilin*).ti,kw,hw. 
164343 
11 (Opipramol or Oxaflozane or Paroxetine or Phenelzine or Pheniprazine or Pipofezin* or 
Pirandamine or Piribedil or Pirlindole or Pivagabine or Pizotyline or Propizepine or 
(Protriptylin* or Pertofrane) or Quinupramine or Quipazine or Reboxetine or Ritanserin or 
Rolipram or Scopolamine or Selegiline or Sertraline or (Setiptiline or Teciptiline) or 
Tandospirone or Teniloxine or Tetrindole or Thiazesim or Thozalinone or Tianeptin* or 
Toloxatone or Tranylcypromine or Trazodone or Trimipramine or 5 Hydroxytryptophan or 
5 HT or Tryptophan or Hydroxytryptophan or Venlafaxine or Viloxazine or Vilazodone or 
Viqualine or Zalospirone or Zimeldine).ti,kw,hw. 
172971 
12 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 663092 
13 DEPRESSION/ or AGITATED DEPRESSION/ or ATYPICAL DEPRESSION/ or ENDOGENOUS 
DEPRESSION/ or INVOLUTIONAL DEPRESSION/ or MAJOR DEPRESSION/ or MASKED 
DEPRESSION/ or MELANCHOLIA/ or ORGANIC DEPRESSION/ or PUERPERAL DEPRESSION/ 
or REACTIVE DEPRESSION/ or "mixed anxiety and depression"/ 
355577 
14 (cease or cessation*or discontinu* or interrupt or interruption or taper* or reduce or drug 
holiday or post withdraw* or postwithdraw* or (stop* adj (taking or using)) or withdraw* 
or terminat* or deprescrib* or de prescrib* or deprescrip* or de prescrip*).ti,ab,kw. 
985146 
15 (prevent* adj3 relaps*).ti,ab,kw. 12176 
16 (prevent* adj3 recurr*).ti,ab,kw. 24142 
17 secondary prevention/ 26698 
18 14 or 15 or 16 or 17 1038745 
19 randomized controlled trial.de. 486141 
20 randomi#ed.ti,ab. 678999 
21 randomly.ab. 349380 
22 factorial$.ti,ab. 29959 
23 (control$ adj3 (trial$ or study or studies or group$)).ti,ab. 1059738 
24 (quasi adj (experimental or random$)).mp. 15035 
25 19 or 20 or 21 or 22 or 23 or 24 1745321 
26 Clinical study/ 285135 
27 case control study/ 127053 
28 Longitudinal study/ 110299 
29 Retrospective study/ 544323 
30 Prospective study/ 405475 
31 Cohort analysis/ 321284 
32 (Cohort adj (study or studies)).mp. 194800 
33 (Case control adj (study or studies)).tw. 104374 
34 (follow up adj (study or studies)).tw. 54788 
35 (observational adj (study or studies)).tw. 107273 
36 (epidemiologic$ adj (study or studies)).tw. 91152 
37 (cross sectional adj (study or studies)).tw. 138593 
38 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 1930183 
39 exp case study/ 96920 
40 (case$ and series).tw. 208351 
41 case report/ 2214717 
42 (case$ adj2 report$).tw. 617208 
43 (case$ adj2 stud$).tw. 249088 
44 39 or 40 or 41 or 42 or 43 2705244 
45 25 or 38 or 44 5827853 
46 12 and 13 and 18 and 45 3560 
47 remove duplicates from 46 3421 
48 (rodent* or rat or rats or mouse or mice or animal model*).ti. 1472370 
49 (smoking or tobacco or nicotine).ti. or smoking cessation.mp. 134529 
50 (antibiotic* or antimicrob* or antifung* or statin*).ti. 192464 
51 (book or editorial or review).pt. 2907167 
52 48 or 49 or 50 or 51 4636647 
53 47 not 52 2670 
 
  
PsycINFO 
PsycINFO (EBSCOhost), inception to 23 March 2017 
Search 
ID# 
Query Items 
found 
S47 S40 NOT S46  346 
S46 S41 OR S42 OR S43 OR S44 OR S45  295014 
S45 TI (editorial or review or guideline)  153362 
S44 TI (rodent* or rat or rats or mouse or mice or animal model*)  112419 
S43 TI (smoking or tobacco or nicotine)  27214 
S42 smoking cessation  16116 
S41 (TI (antibiotic* or antimicrob* or antifung* or statin*)  941 
S40 S11 AND S15 AND S20 AND S39  396 
S39 S27 OR S34 OR S38  22229 
S38 S35 OR S36 OR S37  55044 
S37 (TI (case N1 report*)) or (AB (case N1 report*)) or (KW (case N1 report*))  42544 
S36 DE "Case Report"  22681 
S35 (TI (case N1 series)  or (AB (case N1 series) or (KW (case N1 series)  4044 
S34 S28 OR S29 OR S30 OR S31 OR S32 OR S33  73783 
S33 (TI (cross sectional N1 (study or studies))) or (AB (cross sectional N1 (study or studies))) or 
(KW (cross sectional N1 (study or studies)))  
22502 
S32 (TI (follow up N1 (study or studies))) or (AB (follow up N1 (study or studies))) or (KW 
(follow up N1 (study or studies)))  
12995 
S31 (TI (cohort N1 (study or studies))) or (AB (cohort N1 (study or studies))) or (KW (cohort N1 
(study or studies)))  
17312 
S30 (TI (case N1 control)) or (AB (case N1 control)) or (KW (case N1 control))  10801 
S29 (TI (observational N1 (study or studies))) or (AB (observational N1 (study or studies))) or 
(KW (observational N1 (study or studies)))  
904 
S28 (TI (epidemiologic* N1 (study or studies))) or (AB (epidemiologic* N1 (study or studies))) 
or (KW (epidemiologic* N1 (study or studies)))  
12443 
S27 S21 OR S22 OR S23 OR S24 OR S25 OR S26  10595 
S26 (AB (waitlist* or wait* list* or treatment as usual or TAU) N3 (control or group)))  5909 
S25 (TI (quasi N1 (experimental OR randomi*)) or (AB (quasi N1 (experimental OR randomi*)))  85 
S24 (TI (control* N3 (trial* or study or studies)) or (AB (control* N3 (trial* or study or studies))  72623 
S23 (TI (controlled N1 trial*)) or (AB (controlled N1 trial*)))  32638 
S22 (TI (randomi* control* trial*)) or (AB (randomi* control* trial*))  33209 
S21 (TI (clinic* N1 trial*)) OR (AB (clinic* N1 trial*)))  26774 
S20 S16 OR S17 OR S18 OR S19  453 
S19 (TI (prevent* N3 relaps*)) or (AB (prevent* N3 relaps*)) OR (KW (prevent* N3 relaps*))  5697 
S18 (TI(prevent* N3 recurr*)) or (AB (prevent* N3 recurr*)) OR (KW (prevent* N3 recurr*))  1163 
S17 (TI (deprescrib* or de prescrib* or deprescrip* or de prescrip*)) or (AB (deprescrib* or de 
prescrib* or deprescrip* or de prescrip*)) or (KW (deprescrib* or de prescrib* or 
deprescrip* or de prescrip*))  
463 
S16 (TI (cease or cessation* or discontinu* or interrupt or interruption or taper* or reduce or 
drug holiday or stop or stopping or withdraw* or terminat* post withdraw* or 
postwithdraw*)) or (KW (cease or cessation* or discontinu* or interrupt or interruption or 
taper* or reduce or drug holiday or stop or stopping or withdraw* or terminat* post 
withdraw* or postwithdraw*)) or (MJ (cease or cessation* or discontinu* or interrupt or 
interruption or taper* or reduce or drug holiday or stop or stopping or withdraw* or 
terminat* post withdraw* or postwithdraw*))(TI (cease or cessation* or discontinu* or 
38818 
interrupt or interruption or taper* or reduce or drug holiday or stop or stopping or 
withdraw* or terminat* post withdraw* or postwithdraw*)) or (KW (cease or cessation* 
or discontinu* or interrupt or interruption or taper* or reduce or drug holiday or stop or 
stopping or withdraw* or terminat* post withdraw* or postwithdraw*)) or (MJ (cease or 
cessation* or discontinu* or interrupt or interruption or taper* or reduce or drug holiday 
or stop or sto ...Show Less 
S15 S12 OR S13 OR S14  111656 
S14 (TI (mixed anxiety N2 depressive disorder)) OR (AB (mixed anxiety N2 depressive 
disorder))OR (KW (mixed anxiety N2 depressive disorder))  
363 
S13 (TI (mixed anxiety N2 depression)) OR (AB (mixed anxiety N2 depression)) OR (KW (mixed 
anxiety N2 depression))  
1214 
S12 DE "Major Depression" OR DE "Postpartum Depression" OR DE "Treatment Resistant 
Depression" OR DE "Late Life Depression" OR DE "Recurrent Depression" OR DE "Reactive 
Depression" OR DE "Endogenous Depression" OR DE "Atypical Depression"  
110816 
S11 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10  96482 
S10 (TI (Opipramol or Oxaflozane or Paroxetine or Phenelzine or Pheniprazine or Pipofezin* or 
Pirandamine or Piribedil or Pirlindole or Pivagabine or Pizotyline or Propizepine or 
(Protriptylin* or Pertofrane) or Quinupramine or Quipazine or Reboxetine or Ritanserin or 
Rolipram or Scopolamine or Selegiline or Sertraline or (Setiptiline or Teciptiline) or 
Tandospirone or Teniloxine or Tetrindole or Thiazesim or Thozalinone or Tianeptin* or 
Toloxatone or Tranylcypromine or Trazodone or Trimipramine or 5 Hydroxytryptophan or 
5 HT or Tryptophan or Hydroxytryptophan or Venlafaxine or Viloxazine or Vilazodone or 
Viqualine or Zalospirone or Zimeldine)) or (KW (Opipramol or Oxaflozane or Paroxetine or 
Phenelzine or Pheniprazine or Pipofezin* or Pirandamine or Piribedil or Pirlindole or 
Pivagabine or Pizotyline or Propizepine or (Protriptylin* or Pertofrane) or Quinupramine 
or Quipazine or Reboxetine or Ritanserin or Rolipram or Scopolamine or Selegiline or 
Sertraline or (Setiptiline or Teciptiline) or Tandospirone or Teniloxine or Tetrindole or 
Thiazesim or Thozalinone or Tianeptin* or Toloxatone or Tranylcypromine or Trazodone or 
Trimipramine or 5 Hydroxytryptophan or 5 HT or Tryptophan or Hydroxytryptophan or 
Venlafaxine or Viloxazine or Vilazodone or Viqualine or Zalospirone or Zimeldine)) or (MJ 
(Opipramol or Oxaflozane or Paroxetine or Phenelzine or Pheniprazine or Pipofezin* or 
Pirandamine or Piribedil or Pirlindole or Pivagabine or Pizotyline or Propizepine or 
(Protriptylin* or Pertofrane) or Quinupramine or Quipazine or Reboxetine or Ritanserin or 
Rolipram or Scopolamine or Selegiline or Sertraline or (Setiptiline or Teciptiline) or 
Tandospirone or Teniloxine or Tetrindole or Thiazesim or Thozalinone or Tianeptin* or 
Toloxatone or Tranylcypromine or Trazodone or Trimipramine or 5 Hydroxytryptophan or 
5 HT or Tryptophan or Hydroxytryptophan or Venlafaxine or Viloxazine or Vilazodone or 
Viqualine or Zalospirone or Zimeldine))(TI (Opipramol or Oxaflozane or Paroxetine or 
Phenelzine or Pheniprazine or Pipofezin* or Pirandamine or Piribedil or Pirlindole or 
Pivagabine or Pizotyline or Propizepine or (Protriptylin* or Pertofrane) or Quinupramine 
or Quipazine or Reboxetine or Ritanserin or Rolipram or Scopolamine or Selegiline or 
Sertraline or (Setiptiline or Teciptiline) or Tandospirone or Teniloxine or Tetrindole or 
Thiazesim or Thozalinone or Tianeptin* or Toloxatone or Tranylcypromine or Trazodone or 
Trimipramine or  ...Show Less 
16625 
S9 (TI (Harmaline or Harmine or Hyperforin or Hypericum or John* Wort or Idazoxan or 
Imipramin* or Iprindole or Iproniazid* or Ipsapirone or Imipraminoxide or 
Isocarboxazid*or Lesopitron or Levomilnacipran or Lithium or Lofepramin* or (Lu AA21004 
or Vortioxetine) or Lu AA24530 or LY2216684 or Maprotiline or Medifoxamine or 
Melitracen or Metapramine or Methylphenidate or Mianserin or Milnacipran or Minaprine 
or Mirtazapine or Moclobemide or Monocrotophos or Nefazodone or Nialamide or 
Nitroxazepine or Nomifensine or Norfenfluramine or Nortriptyline or Noxiptilin*)) or (KW 
(Harmaline or Harmine or Hyperforin or Hypericum or John* Wort or Idazoxan or 
Imipramin* or Iprindole or Iproniazid* or Ipsapirone or Imipraminoxide or 
Isocarboxazid*or Lesopitron or Levomilnacipran or Lithium or Lofepramin* or (Lu AA21004 
or Vortioxetine) or Lu AA24530 or LY2216684 or Maprotiline or Medifoxamine or 
Melitracen or Metapramine or Methylphenidate or Mianserin or Milnacipran or Minaprine 
15681 
or Mirtazapine or Moclobemide or Monocrotophos or Nefazodone or Nialamide or 
Nitroxazepine or Nomifensine or Norfenfluramine or Nortriptyline or Noxiptilin*)) or (MJ 
(Harmaline or Harmine or Hyperforin or Hypericum or John* Wort or Idazoxan or 
Imipramin* or Iprindole or Iproniazid* or Ipsapirone or Imipraminoxide or 
Isocarboxazid*or Lesopitron or Levomilnacipran or Lithium or Lofepramin* or (Lu AA21004 
or Vortioxetine) or Lu AA24530 or LY2216684 or Maprotiline or Medifoxamine or 
Melitracen or Metapramine or Methylphenidate or Mianserin or Milnacipran or Minaprine 
or Mirtazapine or Moclobemide or Monocrotophos or Nefazodone or Nialamide or 
Nitroxazepine or Nomifensine or Norfenfluramine or Nortriptyline or Noxiptilin*))(TI 
(Harmaline or Harmine or Hyperforin or Hypericum or John* Wort or Idazoxan or 
Imipramin* or Iprindole or Iproniazid* or Ipsapirone or Imipraminoxide or 
Isocarboxazid*or Lesopitron or Levomilnacipran or Lithium or Lofepramin* or (Lu AA21004 
or Vortioxetine) or Lu AA24530 or LY2216684 or Maprotiline or Medifoxamine or 
Melitracen or Metapramine or Methylphenidate or Mianserin or Milnacipran or Minaprine 
or Mirtazapine or Moclobemide or Monocrotophos or Nefazodone or Nialamide or 
Nitroxazepine o ...Show Less 
S8 (TI (Agomelatine or Alaproclate or Alnespirone or Amoxapine or Amersergide or 
Amfebutamone or Amiflamine or Amineptine or Amitriptylin* or Amitriptylinoxide or 
Amoxapine or Aripiprazole or Atomoxetine or Tomoxetine or Befloxatone or Benactyzine 
or Binospirone or Brofaromine or Bupropion or Butriptylin*or Caroxazone or Chlopoxiten 
or Cianopramine or Cilobamine or Cilosamine or Cimoxatone or Citalopram or 
(Chlorimipramin* or Clomipramin* or Chlomipramin* or Clorimipramine) or Clorgyline or 
Clovoxamine or Dapoxetine or Deanol or Dibenzepin or Demexiptilin* or Deprenyl or 
Desipramine or Desvenlafaxine or Dibenzepin or Diclofenasin* or Dimetacrin* or 
(Dosulepin or Dothiepin) or Doxepin or Duloxetine or DVS 233 or Enilospirone or 
Eptapirone or Escitalopram or Etoperidone or Femoxetine or Fenfluramin* or Fluotracen 
or Fluoxetine or Fluparoxan or Furazolidone or Fluvoxamine)) or (KW (Agomelatine or 
Alaproclate or Alnespirone or Amoxapine or Amersergide or Amfebutamone or 
Amiflamine or Amineptine or Amitriptylin* or Amitriptylinoxide or Amoxapine or 
Aripiprazole or Atomoxetine or Tomoxetine or Befloxatone or Benactyzine or Binospirone 
or Brofaromine or Bupropion or Butriptylin*or Caroxazone or Chlopoxiten or 
Cianopramine or Cilobamine or Cilosamine or Cimoxatone or Citalopram or 
(Chlorimipramin* or Clomipramin* or Chlomipramin* or Clorimipramine) or Clorgyline or 
Clovoxamine or Dapoxetine or Deanol or Dibenzepin or Demexiptilin* or Deprenyl or 
Desipramine or Desvenlafaxine or Dibenzepin or Diclofenasin* or Dimetacrin* or 
(Dosulepin or Dothiepin) or Doxepin or Duloxetine or DVS 233 or Enilospirone or 
Eptapirone or Escitalopram or Etoperidone or Femoxetine or Fenfluramin* or Fluotracen 
or Fluoxetine or Fluparoxan or Furazolidone or Fluvoxamine)) or (MJ (Agomelatine or 
Alnespirone or Alprocolate or Amoxapine or Amersergide or Amfebutamone or 
Amiflamine or Amineptine or Amitriptylin* or Amitriptylinoxide or Amoxapine or 
Aripiprazole or Atomoxetine or Tomoxetine or Befloxatone or Benactyzine or Binospirone 
or Brofaromine or Bupropion or Butriptylin*or Caroxazone or Chlopoxiten or 
Cianopramine or Cilobamine or Cilosamine or Cimoxatone or Citalopram or 
(Chlorimipramin* or Clomipramin* or Chlomipramin* or Clorimipramine) or Clorgyline or 
Clovoxamine or Dapoxetine or Deanol or Dibenzepin or Demexiptilin* or Deprenyl or 
Desipramine or Desvenlafaxine or Dibenzepin or Diclofenasin* or Dimetacrin* or 
(Dosulepin or Dothiepin) or Doxepin or Duloxetine or DVS 233 or Enilospirone or 
Eptapirone or Escitalopram or Etoperidone or Femoxetine or Fenfluramin* or Fluotracen 
or Fluoxetine or Fluparoxan or Furazolidone or Fluvoxamine))(TI (Agomelatine or 
Alaproclate or Alnespirone or Amoxapine or Amersergide or Amfebutamone or 
Amiflamine or Amineptine or Amitriptylin* or Amitriptylinoxide or Amoxapine or 
Aripiprazole or Atomoxetine or Tomoxetine or Befloxatone or Benactyzine or Binospirone 
or Brofaromine or Bupropion or Butriptylin*or Caroxazone or Chlopoxiten or 
Cianopramine or Cilobamine or Cilosamine or Cimoxatone or Citalopram or 
(Chlorimipramin* or Clomipramin* or Chlomipramin* or Clorimipramine) or Clorgyline or 
Clovoxa ...Show Less 
14679 
S7 (TI (psychotropic* or antidepress* or anti depress* or ((serotonin or norepinephrine or 
noradrenaline or nor epinephrine or nor adrenaline or neurotransmitt* or dopamine*) 
and (uptake or reuptake or re-uptake)) or noradrenerg* or antiadrenergic or anti 
adrenergic or SSRI* or SNRI* or TCA* or tricyclic* or tetracyclic* or heterocyclic*)) or (AB 
(psychotropic* or antidepress* or anti depress* or ((serotonin or norepinephrine or 
noradrenaline or nor epinephrine or nor adrenaline or neurotransmitt* or dopamine*) 
and (uptake or reuptake or re-uptake)) or noradrenerg* or antiadrenergic or anti 
adrenergic or SSRI* or SNRI* or TCA* or tricyclic* or tetracyclic* or heterocyclic*)) or (KW 
(psychotropic* or antidepress* or anti depress* or ((serotonin or norepinephrine or 
noradrenaline or nor epinephrine or nor adrenaline or neurotransmitt* or dopamine*) 
and (uptake or reuptake or re-uptake)) or noradrenerg* or antiadrenergic or anti 
adrenergic or SSRI* or SNRI* or TCA* or tricyclic* or tetracyclic* or heterocyclic*)))(TI 
(psychotropic* or antidepress* or anti depress* or ((serotonin or norepinephrine or 
noradrenaline or nor epinephrine or nor adrenaline or neurotransmitt* or dopamine*) 
and (uptake or reuptake or re-uptake)) or noradrenerg* or antiadrenergic or anti 
adrenergic or SSRI* or SNRI* or TCA* or tricyclic* or tetracyclic* or heterocyclic*)) or (AB 
(psychotropic* or antidepress* or anti depress* or ((serotonin or norepinephrine or 
noradrenaline or nor epinephrine or nor adrenaline or neurotransmitt*  ...Show Less 
59965 
S6 DE "Tricyclic Antidepressant Drugs" OR DE "Amitriptyline" OR DE "Chlorimipramine" OR DE 
"Desipramine" OR DE "Doxepin" OR DE "Imipramine" OR DE "Maprotiline" OR DE 
"Nortriptyline"  
8847 
S5 DE "Serotonin Reuptake Inhibitors" OR DE "Citalopram" OR DE "Fluoxetine" OR DE 
"Fluvoxamine" OR DE "Paroxetine" OR DE "Zimeldine”  
13283 
S4 DE "Serotonin Norepinephrine Reuptake Inhibitors" OR DE "Venlafaxine"  1525 
S3 DE "Neurotransmitter Uptake Inhibitors"  326 
S2 DE "Antidepressant Drugs"  17567 
S1 DE "Psychopharmacology" or DE "Neuropsychopharmacology"  9416 
 
  
The Allied and Complementary Medicine Database (AMED) 
AMED (EBSCOhost), inception to 23 March 2017 
Search 
ID# 
Query Items 
found 
S35 S6 AND S10 AND S15 AND S34  21 
S34 S22 OR S30 OR S33  21001 
S33 S31 OR S32  4389 
S32 (TI (case N1 report*)) or (AB (case N1 report*)) OR (KW (case N1 report*))  4079 
S31 (TI (case N1 series)  or (AB (case N1 series) OR (KW (case N1 series)  343 
S30 S23 OR S24 OR S25 OR S26 OR S27 OR S28 OR S29  5541 
S29 (TI (cross sectional N1 (study or studies))) or (AB (cross sectional N1 (study or studies))) OR 
(KW (cross sectional N1 (study or studies)))  
1925 
S28 (TI (follow up N1 (study or studies))) or (AB (follow up N1 (study or studies))) OR (KW 
(follow up N1 (study or studies)))  
760 
S27 (TI (cohort N1 (study or studies))) or (AB (cohort N1 (study or studies))) OR (KW (cohort N1 
(study or studies)))  
1839 
S26 (TI (case N1 control)) or (AB (case N1 control)) OR (KW (case N1 control))  708 
S25 (TI (observational N1 (study or studies)) or (AB (observational N1 (study or studies)) OR 
(KW (observational N1 (study or studies))  
132 
S24 (TI (observational N1 (study or studies)) or (AB (observational N1 (study or studies)) OR 
(KW (observational N1 (study or studies))  
132 
S23 (TI (epidemiologic* N1 (study or studies)) or (AB (epidemiologic* N1 (study or studies)) OR 
(KW (epidemiologic* N1 (study or studies))  
532 
S22 S16 OR S17 OR S18 OR S19 OR S20 OR S21  12226 
S21 (AB (waitlist* or wait* list* or treatment as usual or TAU) N3 (control or group)))  355 
S20 (TI (quasi N1 (experimental OR randomi*)) or (AB (quasi N1 (experimental OR randomi*)))  387 
S19 (TI (control* N3 (trial* or study or studies)) or (AB (control* N3 (trial* or study or studies))  9141 
S18 (TI (controlled N1 trial*)) or (AB (controlled N1 trial*)))  5597 
S17 (TI (randomi* control* trial*)) or (AB (randomi* control* trial*))  5803 
S16 (TI (clinic* N1 trial*)) OR (AB (clinic* N1 trial*)))  3644 
S15 S11 OR S12 OR S13 OR S14  8964 
S14 (TI (prevent* N3 relaps*)) or (AB (prevent* N3 relaps*)) or (KW (prevent* N3 relaps*))  22 
S13 (TI(prevent* N3 recurr*)) or (AB (prevent* N3 recurr*)) or (KW (prevent* N3 recurr*))  31 
S12 (TI (deprescrib* or de prescrib* or deprescrip* or de prescrip*)) or (AB (deprescrib* or de 
prescrib* or deprescrip* or de prescrip*)) or (KW (deprescrib* or de prescrib* or 
deprescrip* or de prescrip*))  
22 
S11 (TI (cease or cessation* or discontinu* or interrupt or interruption or taper* or reduce or 
drug holiday or stop or stopping or withdraw* or terminat*)) or (AB (cease or cessation* 
or continuation or discontinu* or interrupt or interruption or taper* or reduce or drug 
holiday or stop or stopping or withdraw* or terminat*)) or (KW (cease or cessation* or 
continuation or discontinu* or interrupt or interruption or taper* or reduce or drug 
holiday or stop or stopping or withdraw* or terminat*))  
89 
S10 S7 OR S8 OR S9  6074 
S9 (TI ( depressive disorder or depression or mixed anxiety)) or (AB (depressive disorder or 
depression or mixed anxiety)) or (KW (depressive disorder or depression or mixed 
anxiety))  
604 
S8 (DE "ADJUSTMENT DISORDERS")  15 
S7 (DE "DEPRESSION") OR (DE "DEPRESSIVE DISORDER") OR (DE "DEPRESSIVE DISORDERS")  2988 
S6 S1 OR S2 OR S3 OR S4 OR S5  2046 
S5 (TI (Opipramol or Oxaflozane or Paroxetine or Phenelzine or Pheniprazine or Pipofezin* or 142 
Pirandamine or Piribedil or Pirlindole or Pivagabine or Pizotyline or Propizepine or 
(Protriptylin* or Pertofrane) or Quinupramine or Quipazine or Reboxetine or Ritanserin or 
Rolipram or Scopolamine or Selegiline or Sertraline or (Setiptiline or Teciptiline) or 
Tandospirone or Teniloxine or Tetrindole or Thiazesim or Thozalinone or Tianeptin* or 
Toloxatone or Tranylcypromine or Trazodone or Trimipramine or 5 Hydroxytryptophan or 
5 HT or Tryptophan or Hydroxytryptophan or Venlafaxine or Viloxazine or Vilazodone or 
Viqualine or Zalospirone or Zimeldine)) or (KW (Opipramol or Oxaflozane or Paroxetine or 
Phenelzine or Pheniprazine or Pipofezin* or Pirandamine or Piribedil or Pirlindole or 
Pivagabine or Pizotyline or Propizepine or (Protriptylin* or Pertofrane) or Quinupramine 
or Quipazine or Reboxetine or Ritanserin or Rolipram or Scopolamine or Selegiline or 
Sertraline or (Setiptiline or Teciptiline) or Tandospirone or Teniloxine or Tetrindole or 
Thiazesim or Thozalinone or Tianeptin* or Toloxatone or Tranylcypromine or Trazodone or 
Trimipramine or 5 Hydroxytryptophan or 5 HT or Tryptophan or Hydroxytryptophan or 
Venlafaxine or Viloxazine or Vilazodone or Viqualine or Zalospirone or Zimeldine)) or (MJ 
(Opipramol or Oxaflozane or Paroxetine or Phenelzine or Pheniprazine or Pipofezin* or 
Pirandamine or Piribedil or Pirlindole or Pivagabine or Pizotyline or Propizepine or 
(Protriptylin* or Pertofrane) or Quinupramine or Quipazine or Reboxetine or Ritanserin or 
Rolipram or Scopolamine or Selegiline or Sertraline or (Setiptiline or Teciptiline) or 
Tandospirone or Teniloxine or Tetrindole or Thiazesim or Thozalinone or Tianeptin* or 
Toloxatone or Tranylcypromine or Trazodone or Trimipramine or 5 Hydroxytryptophan or 
5 HT or Tryptophan or Hydroxytryptophan or Venlafaxine or Viloxazine or Vilazodone or 
Viqualine or Zalospirone or Zimeldine))(TI (Opipramol or Oxaflozane or Paroxetine or 
Phenelzine or Pheniprazine or Pipofezin* or Pirandamine or Piribedil or Pirlindole or 
Pivagabine or Pizotyline or Propizepine or (Protriptylin* or Pertofrane) or Quinupramine 
or Quipazine or Reboxetine or Ritanserin or Rolipram or Scopolamine or Selegiline or 
Sertraline or (Setiptiline or Teciptiline) or Tandospirone or Teniloxine or Tetrindole or 
Thiazesim or Thozalinone or Tianeptin* or Toloxatone or Tranylcypromine or Trazodone or 
Trimipramine or  ...Show Less 
S4 (TI (Harmaline or Harmine or Hyperforin or Hypericum or John* Wort or Idazoxan or 
Imipramin* or Iprindole or Iproniazid* or Ipsapirone or Imipraminoxide or 
Isocarboxazid*or Lesopitron or Levomilnacipran or Lithium or Lofepramin* or (Lu AA21004 
or Vortioxetine) or Lu AA24530 or LY2216684 or Maprotiline or Medifoxamine or 
Melitracen or Metapramine or Methylphenidate or Mianserin or Milnacipran or Minaprine 
or Mirtazapine or Moclobemide or Monocrotophos or Nefazodone or Nialamide or 
Nitroxazepine or Nomifensine or Norfenfluramine or Nortriptyline or Noxiptilin*)) or (KW 
(Harmaline or Harmine or Hyperforin or Hypericum or John* Wort or Idazoxan or 
Imipramin* or Iprindole or Iproniazid* or Ipsapirone or Imipraminoxide or 
Isocarboxazid*or Lesopitron or Levomilnacipran or Lithium or Lofepramin* or (Lu AA21004 
or Vortioxetine) or Lu AA24530 or LY2216684 or Maprotiline or Medifoxamine or 
Melitracen or Metapramine or Methylphenidate or Mianserin or Milnacipran or Minaprine 
or Mirtazapine or Moclobemide or Monocrotophos or Nefazodone or Nialamide or 
Nitroxazepine or Nomifensine or Norfenfluramine or Nortriptyline or Noxiptilin*)) or (MJ 
(Harmaline or Harmine or Hyperforin or Hypericum or John* Wort or Idazoxan or 
Imipramin* or Iprindole or Iproniazid* or Ipsapirone or Imipraminoxide or 
Isocarboxazid*or Lesopitron or Levomilnacipran or Lithium or Lofepramin* or (Lu AA21004 
or Vortioxetine) or Lu AA24530 or LY2216684 or Maprotiline or Medifoxamine or 
Melitracen or Metapramine or Methylphenidate or Mianserin or Milnacipran or Minaprine 
or Mirtazapine or Moclobemide or Monocrotophos or Nefazodone or Nialamide or 
Nitroxazepine or Nomifensine or Norfenfluramine or Nortriptyline or Noxiptilin*))(TI 
(Harmaline or Harmine or Hyperforin or Hypericum or John* Wort or Idazoxan or 
Imipramin* or Iprindole or Iproniazid* or Ipsapirone or Imipraminoxide or 
Isocarboxazid*or Lesopitron or Levomilnacipran or Lithium or Lofepramin* or (Lu AA21004 
or Vortioxetine) or Lu AA24530 or LY2216684 or Maprotiline or Medifoxamine or 
Melitracen or Metapramine or Methylphenidate or Mianserin or Milnacipran or Minaprine 
or Mirtazapine or Moclobemide or Monocrotophos or Nefazodone or Nialamide or 
Nitroxazepine o ...Show Less 
436 
S3 (TI (Agomelatine or Alaproclate or Alnespirone or Amoxapine or Amersergide or 
Amfebutamone or Amiflamine or Amineptine or Amitriptylin* or Amitriptylinoxide or 
Amoxapine or Aripiprazole or Atomoxetine or Tomoxetine or Befloxatone or Benactyzine 
or Binospirone or Brofaromine or Bupropion or Butriptylin*or Caroxazone or Chlopoxiten 
or Cianopramine or Cilobamine or Cilosamine or Cimoxatone or Citalopram or 
(Chlorimipramin* or Clomipramin* or Chlomipramin* or Clorimipramine) or Clorgyline or 
Clovoxamine or Dapoxetine or Deanol or Dibenzepin or Demexiptilin* or Deprenyl or 
Desipramine or Desvenlafaxine or Dibenzepin or Diclofenasin* or Dimetacrin* or 
(Dosulepin or Dothiepin) or Doxepin or Duloxetine or DVS 233 or Enilospirone or 
Eptapirone or Escitalopram or Etoperidone or Femoxetine or Fenfluramin* or Fluotracen 
or Fluoxetine or Fluparoxan or Furazolidone or Fluvoxamine)) or (KW (Agomelatine or 
Alaproclate or Alnespirone or Amoxapine or Amersergide or Amfebutamone or 
Amiflamine or Amineptine or Amitriptylin* or Amitriptylinoxide or Amoxapine or 
Aripiprazole or Atomoxetine or Tomoxetine or Befloxatone or Benactyzine or Binospirone 
or Brofaromine or Bupropion or Butriptylin*or Caroxazone or Chlopoxiten or 
Cianopramine or Cilobamine or Cilosamine or Cimoxatone or Citalopram or 
(Chlorimipramin* or Clomipramin* or Chlomipramin* or Clorimipramine) or Clorgyline or 
Clovoxamine or Dapoxetine or Deanol or Dibenzepin or Demexiptilin* or Deprenyl or 
Desipramine or Desvenlafaxine or Dibenzepin or Diclofenasin* or Dimetacrin* or 
(Dosulepin or Dothiepin) or Doxepin or Duloxetine or DVS 233 or Enilospirone or 
Eptapirone or Escitalopram or Etoperidone or Femoxetine or Fenfluramin* or Fluotracen 
or Fluoxetine or Fluparoxan or Furazolidone or Fluvoxamine)) or (MJ (Agomelatine or 
Alaprocolate or Alnespirone or Amoxapine or Amersergide or Amfebutamone or 
Amiflamine or Amineptine or Amitriptylin* or Amitriptylinoxide or Amoxapine or 
Aripiprazole or Atomoxetine or Tomoxetine or Befloxatone or Benactyzine or Binospirone 
or Brofaromine or Bupropion or Butriptylin*or Caroxazone or Chlopoxiten or 
Cianopramine or Cilobamine or Cilosamine or Cimoxatone or Citalopram or 
(Chlorimipramin* or Clomipramin* or Chlomipramin* or Clorimipramine) or Clorgyline or 
Clovoxamine or Dapoxetine or Deanol or Dibenzepin or Demexiptilin* or Deprenyl or 
Desipramine or Desvenlafaxine or Dibenzepin or Diclofenasin* or Dimetacrin* or 
(Dosulepin or Dothiepin) or Doxepin or Duloxetine or DVS 233 or Enilospirone or 
Eptapirone or Escitalopram or Etoperidone or Femoxetine or Fenfluramin* or Fluotracen 
or Fluoxetine or Fluparoxan or Furazolidone or Fluvoxamine))(TI (Agomelatine or 
Alaproclate or Alnespirone or Amoxapine or Amersergide or Amfebutamone or 
Amiflamine or Amineptine or Amitriptylin* or Amitriptylinoxide or Amoxapine or 
Aripiprazole or Atomoxetine or Tomoxetine or Befloxatone or Benactyzine or Binospirone 
or Brofaromine or Bupropion or Butriptylin*or Caroxazone or Chlopoxiten or 
Cianopramine or Cilobamine or Cilosamine or Cimoxatone or Citalopram or 
(Chlorimipramin* or Clomipramin* or Chlomipramin* or Clorimipramine) or Clorgyline or 
Clovoxa ...Show Less 
84 
S2 (TI (psychotropic* or antidepress* or anti depress* or ((serotonin or norepinephrine or 
noradrenaline or nor epinephrine or nor adrenaline or neurotransmitt* or dopamine*) 
and (uptake or reuptake or re-uptake)) or noradrenerg* or antiadrenergic or anti 
adrenergic or SSRI* or SNRI* or TCA* or tricyclic* or tetracyclic* or heterocyclic*)) or (AB 
(psychotropic* or antidepress* or anti depress* or ((serotonin or norepinephrine or 
noradrenaline or nor epinephrine or nor adrenaline or neurotransmitt* or dopamine*) 
and (uptake or reuptake or re-uptake)) or noradrenerg* or antiadrenergic or anti 
adrenergic or SSRI* or SNRI* or TCA* or tricyclic* or tetracyclic* or heterocyclic*)) or (KW 
(psychotropic* or antidepress* or anti depress* or ((serotonin or norepinephrine or 
noradrenaline or nor epinephrine or nor adrenaline or neurotransmitt* or dopamine*) 
and (uptake or reuptake or re-uptake)) or noradrenerg* or antiadrenergic or anti 
adrenergic or SSRI* or SNRI* or TCA* or tricyclic* or tetracyclic* or heterocyclic*)))(TI 
(psychotropic* or antidepress* or anti depress* or ((serotonin or norepinephrine or 
noradrenaline or nor epinephrine or nor adrenaline or neurotransmitt* or dopamine*) 
and (uptake or reuptake or re-uptake)) or noradrenerg* or antiadrenergic or anti 
adrenergic or SSRI* or SNRI* or TCA* or tricyclic* or tetracyclic* or heterocyclic*)) or (AB 
(psychotropic* or antidepress* or anti depress* or ((serotonin or norepinephrine or 
1546 
noradrenaline or nor epinephrine or nor adrenaline or neurotransmitt*  ...Show Less 
S1 (DE "antidepressive agents")  313 
 
  
Health Management Information Consortium (HMIC) 
HMIC, inception to 24 March 2017 
Search 
ID# 
Query Items 
found 
1 "PSYCHOPHARMACOLOGY"/  42 
2 "PSYCHOTROPIC DRUGS"/ 135 
3 exp "ANTI DEPRESSANTS"/ 389 
4 exp "SELECTIVE SEROTONIN REUPTAKE INHIBITORS"/  35 
5 (psychotropic* OR antidepress* OR anti depress* OR ((serotonin OR norepinephrine OR 
noradrenaline OR nor epinephrine OR nor adrenaline OR neurotransmitt* OR dopamine*) 
AND (uptake OR reuptake OR re-uptake)) OR noradrenerg* OR antiadrenergic OR anti 
adrenergic OR SSRI* OR SNRI* OR TCA* OR tricyclic* OR tetracyclic* OR 
heterocyclic*).ti,ab  
929 
6 (Agomelatine OR Alaproclate OR Alnespirone OR Amoxapine OR Amersergide OR 
Amfebutamone OR Amiflamine OR Amineptine OR Amitriptylin* OR Amitriptylinoxide OR 
Amoxapine OR Aripiprazole OR Atomoxetine OR Tomoxetine OR Befloxatone OR 
Benactyzine OR Binospirone OR Brofaromine OR Bupropion OR Butriptylin* OR 
Caroxazone OR Chlopoxiten OR Cianopramine OR Cilobamine OR Cilosamine OR 
Cimoxatone OR Citalopram OR Chlorimipramin* OR Clomipramin* OR Chlomipramin* OR 
Clorimipramine OR Clorgyline OR Clovoxamine OR Dapoxetine OR Deanol OR 
Demexiptilin* OR Deprenyl OR Desipramine OR Desvenlafaxine OR Dibenzepin OR 
Diclofenasin* OR Dimetacrin* OR Dosulepin OR Dothiepin OR Doxepin OR Duloxetine OR 
DVS 233 OR Enilospirone OR Eptapirone OR Escitalopram OR Etoperidone OR Femoxetine 
OR Fenfluramin* OR Fluotracen OR Fluoxetine OR Fluparoxan OR Furazolidone OR 
Fluvoxamine).ti,ab  
220 
7 (Harmaline OR Harmine OR Hyperforin OR Hypericum OR John* Wort OR Idazoxan OR 
Imipramin* OR Iprindole OR Iproniazid* OR Ipsapirone OR Imipraminoxide OR 
Isocarboxazid*or Lesopitron OR Levomilnacipran OR Lithium OR Lofepramin* OR Lu 
AA21004 OR Vortioxetine OR Lu AA24530 OR LY2216684 OR Maprotiline OR 
Medifoxamine OR Melitracen OR Metapramine OR Methylphenidate OR Mianserin OR 
Milnacipran OR Minaprine OR Mirtazapine OR Moclobemide OR Monocrotophos OR 
Nefazodone OR Nialamide OR Nitroxazepine OR Nomifensine OR Norfenfluramine OR 
Nortriptyline OR Noxiptilin*).ti,ab  
126 
8 (Opipramol OR Oxaflozane OR Paroxetine OR Phenelzine OR Pheniprazine OR Pipofezin* 
OR Pirandamine OR Piribedil OR Pirlindole OR Pivagabine OR Pizotyline OR Propizepine OR 
Protriptylin* OR Pertofrane OR Quinupramine OR Quipazine OR Reboxetine OR Ritanserin 
OR Rolipram OR Scopolamine OR Selegiline OR Sertraline OR Setiptiline OR Teciptiline OR 
Tandospirone OR Teniloxine OR Tetrindole OR Thiazesim OR Thozalinone OR Tianeptin* 
OR Toloxatone OR Tranylcypromine OR Trazodone OR Trimipramine OR 5 
Hydroxytryptophan OR 5 HT OR Tryptophan OR Hydroxytryptophan OR Venlafaxine OR 
Viloxazine OR Vilazodone OR Viqualine OR Zalospirone OR Zimeldine).ti,ab  
99 
9 (1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 8)  1307 
10 "MOOD DISORDERS"/  90 
11 "DEPRESSION"/  2608 
12 (depressive disorder OR depression OR mixed anxiety).ti,ab  4422 
13 (10 OR 11 OR 12) 4909 
14 (cease OR cessation* OR discontinu* OR interrupt OR interruption OR taper* OR reduce 
OR drug holiday OR stop OR stopping OR withdraw* OR terminat* OR deprescrib* OR de 
prescrib* OR deprescrip* OR de prescrip*).ti,ab b  
14611 
15 (prevent* ADJ3 relaps*).ti,ab 144 
16 (prevent* ADJ3 recurr*).ti,ab  91 
17 (14 OR 15 OR 16)  14771 
18 "RANDOMISED CONTROLLED TRIALS"/  2352 
19 (randomi#ed OR randomi#ation).ti,ab 6465 
20 (randomly).ab 2789 
21 (trial).ti,ab trial.ti,ab  6264 
22 (groups).ab 23383 
23 (control* ADJ3 (trial* OR study OR studies)).ti,ab (control* adj3 (trial* or study or 
studies)).ti,ab  
6624 
24 (quasi ADJ (experimental OR random*)).ti,ab (quasi adj (experimental or random*)).ti,ab  410 
25 ((waitlist* OR wait* list* OR treatment as usual OR TAU) ADJ3 (control OR group)).ab  87 
26 (18 OR 19 OR 20 OR 21 OR 22 OR 23 OR 24 OR 25) (18 OR 19 OR 20 OR 21 OR 22 OR 23 OR 
24 OR 25) 
33018 
27 "COHORT STUDIES"/  1010 
28 "PROSPECTIVE STUDIES"/ 198 
29 "LONGITUDINAL STUDIES"/ 542 
30 (Case control).ti,ab  1403 
31 (cohort ADJ (study OR studies)).ti,ab  3279 
32 (Cohort analy*).ti,ab 134 
33 (Follow up ADJ (study OR studies)).ti,ab 633 
34 (observational ADJ (study OR studies)).ti,ab  1373 
35 (epidemiologic* ADJ (study OR studies)).ti,ab  951 
36 (Longitudinal).ti,ab  3139 
37 (Retrospective).ti,ab  3045 
38 (Cross sectional).ti,ab 4708 
39 (27 OR 28 OR 29 OR 30 OR 31 OR 32 OR 33 OR 34 OR 35 OR 36 OR 37 OR 38)  16417 
40 (Case series).ti,ab  114 
41 (Case* report*).ti,ab  323 
42 (Case* stud*).ti,ab  6076 
43 (40 OR 41 OR 42)  6487 
44 (26 OR 39 OR 43)  50227 
45 (9 AND 13 AND 17 AND 44) 56 
46 (rodent* OR rat OR rats OR mouse OR mice OR animal model*).ti  139 
47 (smoking OR tobacco OR nicotine).ti (smoking OR tobacco OR nicotine).ti  3936 
48 (smoking cessation).ti,ab 1191 
49 (antibiotic* OR antimicrob* OR antifung* OR statin*).ti 796 
50 (46 OR 47 OR 48 OR 49) 5138 
51 45 NOT 50 48 
 
  
OpenGrey 
OpenGrey (http://www.opengrey.eu/), inception to 24 March 2017 
Query Items found 
(antidepressant* OR SSRI* OR serotonin reuptake 
inhibitor* OR SNRI* OR noradrenaline reuptake inhibitor* 
OR norepineprhine reuptake inhibitor* or tricyclic 
antidepressant*) AND (trial* OR RCT* OR observational OR 
cohort* OR case series OR case report*) 28 
 
WHO International Clinical Trials Registry platform (WHO ICTRP). 
WHO ICTRP (http://apps.who.int/trialsearch/default.aspx), inception to 24 March 2017 
Query Items found 
Depression AND prevent* AND relapse 110 
Depression AND prevent* AND recurr* 33 
Antidepressant* AND cease 1 
Antidepressant* AND cessation 3 
Antidepressant* AND discontinuation 13 
Antidepressant* AND taper* 11 
Antidepressant* AND reduce 6 
Antidepressant*  AND stop* 4 
Antidepressant* AND withdraw* 8 
Antidepressant* AND terminat* 3 
Antidepressant* AND deprescrib* 3 
SSRI* AND cease 0 
SSRI* AND cessation 0 
SSRI* AND discontinuation 1 
SSRI* AND taper* 3 
SSRI* AND reduce 3 
SSRI*  AND stop* 1 
SSRI* AND withdraw* 1 
SSRI* AND terminat* 0 
SSRI* AND deprescrib* 0 
SNRI* AND cease 0 
SNRI* AND cessation 0 
SNRI* AND discontinuation 0 
SNRI* AND taper* 1 
SNRI* AND reduce 0 
SNRI*  AND stop* 0 
SNRI* AND withdraw* 0 
SNRI* AND terminat* 0 
SNRI* AND deprescrib* 0 
TCA AND cease 
Only brought up records for non-psychiatric 
indications e.g. diabetes, stem cells, 
transplantations, cancer 
TCA AND cessation 
See above 
TCA AND discontinuation 
See above 
TCA AND taper* 
See above 
TCA AND reduce 
See above 
TCA AND stop* 
See above 
TCA AND withdraw* 
See above 
TCA AND terminat* 
See above 
TCA AND deprescrib* 
See above 
tricyclic antidepressant* AND cease 0 
tricyclic antidepressant* AND cessation 1 
tricyclic antidepressant* AND discontinuation 0 
tricyclic antidepressant* AND taper* 1 
tricyclic antidepressant* AND reduce 2 
tricyclic antidepressant*  AND stop* 0 
tricyclic antidepressant* AND withdraw* 1 
tricyclic antidepressant* AND terminat* 0 
tricyclic antidepressant* AND deprescrib* 1 
citalopram AND cease 0 
citalopram AND cessation 0 
citalopram AND discontinuation 4 
citalopram AND taper* 2 
citalopram AND reduce 2 
citalopram  AND stop* 1 
citalopram AND withdraw* 0 
citalopram AND terminat* 0 
citalopram AND deprescrib* 0 
escitalopram AND cease 0 
escitalopram AND cessation 1 
escitalopram AND discontinuation 6 
escitalopram AND taper* 2 
escitalopram AND reduce 1 
escitalopram  AND stop* 0 
escitalopram AND withdraw* 2 
escitalopram AND terminat* 2 
escitalopram AND deprescrib* 0 
fluoxetine AND cease 0 
fluoxetine AND cessation 1 
fluoxetine AND discontinuation 1 
fluoxetine AND taper* 1 
fluoxetine AND reduce 2 
fluoxetine  AND stop* 2 
fluoxetine AND withdraw* 0 
fluoxetine AND terminat* 0 
fluoxetine AND deprescrib* 0 
fluvoxamine AND cease 0 
fluvoxamine AND cessation 0 
fluvoxamine AND discontinuation 0 
fluvoxamine AND taper* 1 
fluvoxamine AND reduce 0 
fluvoxamine  AND stop* 0 
fluvoxamine AND withdraw* 0 
fluvoxamine AND terminat* 0 
fluvoxamine AND deprescrib* 0 
paroxetine AND cessation 0 
paroxetine AND discontinuation 1 
paroxetine AND taper* 0 
paroxetine AND reduce 0 
paroxetine  AND stop* 0 
paroxetine AND withdraw* 1 
paroxetine AND terminat* 0 
paroxetine AND deprescrib* 0 
sertraline AND cease 3 
sertraline AND cessation 0 
sertraline AND discontinuation 1 
sertraline AND taper* 1 
sertraline AND reduce 6 
sertraline  AND stop* 4 
sertraline AND withdraw* 0 
sertraline AND terminat* 1 
sertraline AND deprescrib* 0 
duloxetine AND cease 0 
duloxetine AND cessation 0 
duloxetine AND discontinuation 1 
duloxetine AND taper* 1 
duloxetine AND reduce 2 
duloxetine  AND stop* 0 
duloxetine AND withdraw* 0 
duloxetine AND terminat* 0 
duloxetine AND deprescrib* 0 
venlafaxine AND cease 0 
venlafaxine AND cessation 0 
venlafaxine AND discontinuation 0 
venlafaxine AND taper* 5 
venlafaxine AND reduce 1 
venlafaxine  AND stop* 0 
venlafaxine AND withdraw* 1 
venlafaxine AND terminat* 0 
venlafaxine AND deprescrib* 0 
mirtazapine AND cease 1 
mirtazapine AND cessation 0 
mirtazapine AND discontinuation 0 
mirtazapine AND taper* 1 
mirtazapine AND reduce 1 
mirtazapine  AND stop* 2 
mirtazapine AND withdraw* 2 
mirtazapine AND terminat* 0 
mirtazapine AND deprescrib* 0 
  Total number of hits 278 
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TABLE A: EXCLUDED STUDIES 
 
 Reference Reason for exclusion 
1 Anonymous. Home-based programme significantly reduces depressive 
symptoms and improves health status in chronically ill older adults with 
minor depression or dysthymia. Evidence-Based Healthcare and Public 
Health 2004;8(5):257-58. doi: 
http://dx.doi.org/10.1016/j.ehbc.2004.08.035 
Population has minor depression or 
dysthymia 
2 Apil SRA, Spinhoven P, Haffmans PMJ, et al. Two-year follow-up of a 
randomized controlled trial of stepped care cognitive behavioral 
therapy to prevent recurrence of depression in an older population. 
International Journal of Geriatric Psychiatry 2014;29(3):317-25. doi: 
http://dx.doi.org/10.1002/gps.4010 
Intervention is not aimed at antidepressant 
reduction/discontinuation. 
3 Aronson TA, Shukla S. Long-term continuation antidepressant 
treatment: A comparison study. Journal of Clinical Psychiatry 
1989;50(8):285-89. 
Population included some bipolar patients 
(>10%) 
4 Baldwin DS, Cooper JA, Huusom AKT, et al. A double-blind, randomized, 
parallel-group, flexible-dose study to evaluate the tolerability, efficacy 
and effects of treatment discontinuation with escitalopram and 
paroxetine in patients with major depressive disorder. International 
Clinical Psychopharmacology 2006;21(3):159-69. doi: 
http://dx.doi.org/10.1097/01.yic.0000194377.88330.1d 
Intervention is not aimed at antidepressant 
reduction/discontinuation (interruption 
study) 
5 Bialos D, Giller E, Jatlow P, et al. Recurrence of depression after 
discontinuation of long-term amitriptyline treatment. American Journal 
of Psychiatry 1982;139(3):325-9. doi: 
https://dx.doi.org/10.1176/ajp.139.3.325 
Intervention is not aimed at antidepressant 
reduction/discontinuation 
6 Bieling PJ, Hawley LL, Bloch RT, et al. Treatment-specific changes in 
decentering following mindfulness-based cognitive therapy versus 
antidepressant medication or placebo for prevention of depressive 
relapse. Journal of Consulting and Clinical Psychology 2012;80(3):365-
72. doi: http://dx.doi.org/10.1037/a0027483 
Outcomes were cognitive changes (neither a 
primary nor secondary outcome of the 
review) 
7 Bockting CL, Spinhoven P, Wouters LF, et al. Long-term effects of 
preventive cognitive therapy in recurrent depression: a 5.5-year follow-
up study. Journal of Clinical Psychiatry 2009;70(12):1621-8. doi: 
https://dx.doi.org/10.4088/JCP.08m04784blu 
Intervention is not aimed at antidepressant 
reduction/discontinuation 
8 Bockting CLH, Schene AH, Koeter HWJ, et al. Preventing 
relapse/recurrence in recurrent depression with cognitive therapy: A 
randomized controlled trial. Journal of Consulting and Clinical 
Psychology 2005;73(4):647-57. doi: http://dx.doi.org/10.1037/0022-
006X.73.4.647 
Intervention is not aimed at antidepressant 
reduction/discontinuation 
9 Bockting CLH, Smid NH, Koeter MWJ, et al. Enduring effects of 
Preventive Cognitive Therapy in adults remitted from recurrent 
depression: A 10 year follow-up of a randomized controlled trial. Journal 
of Affective Disorders 2015;185:188-94. doi: 
http://dx.doi.org/10.1016/j.jad.2015.06.048 
Intervention is not aimed at antidepressant 
reduction/discontinuation 
10 Bockting CLH, Spinhoven P, Koeter MWJ, et al. Differential predictors of 
response to preventive cognitive therapy in recurrent depression: A 2-
year prospective study. Psychotherapy and Psychosomatics 
2006;75(4):229-36. doi: http://dx.doi.org/10.1159/000092893 
Intervention is not aimed at antidepressant 
reduction/discontinuation 
11 Bockting CLH, Ten Doesschate MC, Spijker J, et al. Continuation and 
maintenance use of antidepressants in recurrent depression. 
Psychotherapy and Psychosomatics 2008;77(1):17-26. doi: 
http://dx.doi.org/10.1159/000110056 
Observational study not concerning 
reduction/discontinuation of antidepressants 
12 Curtin F, Schulz P. Relapse prevention and antidepressants. Lancet 
2003;361(9375):2158-59; author reply 59. 
Letter concerning a systematic review 
13 Dallal A, Chouinard G. Withdrawal and rebound symptoms associated 
with abrupt discontinuation of venlafaxine. Journal of Clinical 
Psychopharmacology 1998;18(4):343-44. doi: 10.1097/00004714-
199808000-00017 
Study design was case series 
14 Dobson KS, Hollon SD, Dimidjian S, et al. Randomized Trial of Behavioral 
Activation, Cognitive Therapy, and Antidepressant Medication in the 
Prevention of Relapse and Recurrence in Major Depression. Journal of 
Consulting and Clinical Psychology 2008;76(3):468-77. doi: 
http://dx.doi.org/10.1037/0022-006X.76.3.468 
Intervention is not aimed at antidepressant 
reduction/discontinuation 
3 
 
15 Fava GA, Rafanelli C, Cazzaro M, et al. Well-being therapy. A novel 
psychotherapeutic approach for residual symptoms of affective 
disorders. Psychological Medicine 1998;28(2):475-80. doi: 
http://dx.doi.org/10.1017/S0033291797006363 
Intervention is not aimed at antidepressant 
reduction/discontinuation 
16 Flint AJ, Rifat SL. Recurrence of first-episode geriatric depression after 
discontinuation of maintenance antidepressants. American Journal of 
Psychiatry 1999;156(6):943-5. doi: 
https://dx.doi.org/10.1176/ajp.156.6.943 
Study of relapse prevention, not 
antidepressant discontinuation. 
17 Frank E, Kupfer DJ, Perel JM. Early recurrence in unipolar depression. 
Archives of General Psychiatry 1989;46(5):397-400. 
Study of relapse prevention, not 
antidepressant discontinuation. 
18 Godfrin KA, van Heeringen C. The effects of mindfulness-based cognitive 
therapy on recurrence of depressive episodes, mental health and 
quality of life: A randomized controlled study. Behaviour Research and 
Therapy 2010;48(8):738-46. doi: 
http://dx.doi.org/10.1016/j.brat.2010.04.006 
Intervention is not aimed at antidepressant 
reduction/discontinuation 
19 Howell CA, Turnbull DA, Beilby JJ, et al. Preventing relapse of depression 
in primary care: a pilot study of the "Keeping the blues away" program. 
The Medical journal of Australia 2008;188(12 Suppl):S138-41. 
Intervention is not aimed at antidepressant 
reduction/discontinuation 
20 Huijbers MJ, Spinhoven P, Spijker J, et al. Adding mindfulness-based 
cognitive therapy to maintenance antidepressant medication for 
prevention of relapse/recurrence in major depressive disorder: 
Randomised controlled trial. Journal of Affective Disorders 2015;187:54-
61. doi: http://dx.doi.org/10.1016/j.jad.2015.08.023 
Intervention is not aimed at antidepressant 
reduction/discontinuation 
21 Kinser PA, Elswick RK, Kornstein S. Potential long-term effects of a mind-
body intervention for women with major depressive disorder: sustained 
mental health improvements with a pilot yoga intervention. Arch 
Psychiatr Nurs 2014;28(6):377-83. doi: 
https://dx.doi.org/10.1016/j.apnu.2014.08.014 
Intervention is not aimed at antidepressant 
reduction/discontinuation 
22 Kuehner C. An evaluation of the 'Coping with Depression Course' for 
relapse prevention with unipolar depressed patients. Psychotherapy and 
Psychosomatics 2005;74(4):254-59. doi: 
http://dx.doi.org/10.1159/000085150 
Intervention is not aimed at antidepressant 
reduction/discontinuation 
23 Ludman E, Katon W, Bush T, et al. Behavioural factors associated with 
symptom outcomes in a primary care-based depression prevention 
intervention trial. Psychological Medicine 2003;33(6):1061-70. doi: 
http://dx.doi.org/10.1017/S003329170300816X 
Intervention is not aimed at antidepressant 
reduction/discontinuation 
24 Ludman E, Von Korff M, Katon W, et al. The design, implementation, 
and acceptance of a primary care-based intervention to prevent 
depression relapse. International Journal of Psychiatry in Medicine 
2000;30(3):229-45. doi: http://dx.doi.org/10.2190/44LK-28E9-RRJ5-
KQVW 
Intervention is not aimed at antidepressant 
reduction/discontinuation 
25 Mago R, Crits-Christoph P. Prevention of recurrent depression with 
cognitive behavioral therapy. Arch Gen Psychiatry 1999;56(5):479-80. 
[published Online First: 1999/05/08] 
Letter commenting on a study already 
included in the review 
26 Meadows GN, Shawyer F, Enticott JC, et al. Mindfulness-based cognitive 
therapy for recurrent depression: A translational research study with 2-
year follow-up. Australian and New Zealand Journal of Psychiatry 
2014;48(8):743-55. doi: http://dx.doi.org/10.1177/0004867414525841 
Intervention is not aimed at antidepressant 
reduction/discontinuation 
27 Michelson D, Fava M, Amsterdam J, et al. Interruption of selective 
serotonin reuptake inhibitor treatment: Double-blind, placebo-
controlled trial. British Journal of Psychiatry 2000;176(APR.):363-68. doi: 
http://dx.doi.org/10.1192/bjp.176.4.363 
Intervention is not aimed at antidepressant 
reduction/discontinuation (interruption 
study) 
28 Montgomery SA, Fava M, Padmanabhan SK, et al. Discontinuation 
symptoms and taper/poststudy-emergent adverse events with 
desvenlafaxine treatment for major depressive disorder. International 
Clinical Psychopharmacology 2009;24(6):296-305. doi: 
http://dx.doi.org/10.1097/YIC.0b013e32832fbb5a 
Study design was pooled analysis of 
prevalence and type of discontinuation 
symptoms after antidepressant 
discontinuation during or at the end of 
placebo controlled trials of treatment of 
depression 
29 Mourad I, Lejoyeux M, Ades J. [Prospective evaluation of antidepressant 
discontinuation]. Encephale 1998;24(3):215-22. 
Study design was case series 
30 Omidi A, Mohammadkhani P, Mohammadi A, et al. Comparing 
mindfulness based cognitive therapy and traditional cognitive behavior 
therapy with treatments as usual on reduction of major depressive 
disorder symptoms. Iranian Red Crescent Medical Journal 
2013;15(2):142-46. doi: http://dx.doi.org/10.5812/ircmj.8018 
Intervention is not aimed at antidepressant 
reduction/discontinuation 
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31 Paykel ES, Scott J, Cornwall PL, et al. Duration of relapse prevention 
after cognitive therapy in residual depression: Follow-up of controlled 
trial. Psychological Medicine 2005;35(1):59-68. doi: 
http://dx.doi.org/10.1017/S003329170400282X 
Intervention is not aimed at antidepressant 
reduction/discontinuation 
32 Paykel ES, Scott J, Teasdale JD, et al. Prevention of relapse in residual 
depression by cognitive therapy. A controlled trial. Archives of General 
Psychiatry 1999;56(9):829-35. doi: 
http://dx.doi.org/10.1001/archpsyc.56.9.829 
Intervention is not aimed at antidepressant 
reduction/discontinuation 
33 Perlis RH, Nierenberg AA, Alpert JE, et al. Effects of adding cognitive 
therapy to fluoxetine dose increase on risk of relapse and residual 
depressive symptoms in continuation treatment of major depressive 
disorder. Journal of Clinical Psychopharmacology 2002;22(5):474-80. 
Intervention is not aimed at antidepressant 
reduction/discontinuation 
34 Petersen TJ, Pava JA, Buchin J, et al. The role of cognitive-behavioral 
therapy and fluoxetine in prevention of recurrence of major depressive 
disorder. Cognitive Therapy and Research 2010;34(1):13-23. doi: 
http://dx.doi.org/10.1007/s10608-007-9166-6 
Intervention is not aimed at antidepressant 
reduction/discontinuation 
35 Rosenbaum JF, Fava M, Hoog SL, et al. Selective serotonin reuptake 
inhibitor discontinuation syndrome: A randomized clinical trial. 
Biological Psychiatry 1998;44(2):77-87. doi: 
http://dx.doi.org/10.1016/S0006-3223%2898%2900126-7 
Intervention is not aimed at antidepressant 
reduction/discontinuation (interruption 
study) 
36 Scott J, Palmer S, Paykel E, et al. Use of cognitive therapy for relapse 
prevention in chronic depression: Cost-effectiveness study. British 
Journal of Psychiatry 2003;182(MAR.):221-27. doi: 
http://dx.doi.org/10.1192/bjp.182.3.221 
Intervention is not aimed at antidepressant 
reduction/discontinuation 
37 Segal ZV, Bieling P, Young T, et al. Antidepressant monotherapy vs 
sequential pharmacotherapy and mindfulness-based cognitive therapy, 
or placebo, for relapse prophylaxis in recurrent depression. Archives of 
General Psychiatry 2010;67(12):1256-64. doi: 
http://dx.doi.org/10.1001/archgenpsychiatry.2010.168 
Intervention is not aimed at antidepressant 
reduction/discontinuation 
38 Shawyer F, Meadows GN, Judd F, et al. The DARE study of relapse 
prevention in depression: Design for a phase 1/2 translational 
randomised controlled trial involving mindfulness-based cognitive 
therapy and supported self monitoring. BMC Psychiatry 2014;12 (1) (no 
pagination)(3) doi: http://dx.doi.org/10.1186/1471-244X-32-3 
Intervention is not aimed at antidepressant 
reduction/discontinuation 
39 Stangier U, Hilling C, Heidenreich T, et al. Maintenance cognitive-
behavioral therapy and manualized psychoeducation in the treatment 
of recurrent depression: A multicenter prospective randomized 
controlled trial. American Journal of Psychiatry 2013;170(6):624-32. doi: 
http://dx.doi.org/10.1176/appi.ajp.2013.12060734 
Intervention is not aimed at antidepressant 
reduction/discontinuation 
40 Stant AD, TenVergert EM, Kluiter H, et al. Cost-effectiveness of a 
psychoeducational relapse prevention program for depression in 
primary care. J Ment Health Policy Econ 2009;12(4):195-204. 
Intervention is not aimed at antidepressant 
reduction/discontinuation 
41 Tang TZ, Derubeis RJ, Hollon SD, et al. Sudden gains in cognitive therapy 
of depression and depression relapse/recurrence. J Consult Clin Psychol 
2007;75(3):404-8. doi: 10.1037/0022-006x.75.3.404 [published Online 
First: 2007/06/15] 
Intervention is not aimed at antidepressant 
reduction/discontinuation 
42 Taylor MP, Reynolds CF, 3rd, Frank E, et al. Which elderly depressed 
patients remain well on maintenance interpersonal psychotherapy 
alone?: report from the Pittsburgh study of maintenance therapies in 
late-life depression. Depress Anxiety 1999;10(2):55-60. 
Intervention is not aimed at antidepressant 
reduction/discontinuation 
43 Teasdale JD, Segal ZV, Williams JM, et al. Prevention of 
relapse/recurrence in major depression by mindfulness-based cognitive 
therapy. J Consult Clin Psychol 2000;68(4):615-23. 
Intervention is not aimed at antidepressant 
reduction/discontinuation 
44 Tint A, Haddad PM, Anderson IM. The effect of rate of antidepressant 
tapering on the incidence of discontinuation symptoms: a randomised 
study.[Erratum appears in J Psychopharmacol. 2009 Nov;23(8):1006]. 
Journal of Psychopharmacology 2008;22(3):330-2. doi: 
https://dx.doi.org/10.1177/0269881107087488 
https://dx.doi.org/10.1177/0269881107081550 
Intervention is not aimed at antidepressant 
reduction/discontinuation (interruption 
study) 
45 Ulfvarson J, Adami J, Wredling R, et al. Controlled withdrawal of 
selective serotonin reuptake inhibitor drugs in elderly patients in 
nursing homes with no indication of depression. European Journal of 
Clinical Pharmacology 2003;59(10):735-40. doi: 
http://dx.doi.org/10.1007/s00228-003-0687-y 
Population had no history of indication for 
antidepressant use 
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46 van Geffen EC, Hugtenburg JG, Heerdink ER, et al. Discontinuation 
symptoms in users of selective serotonin reuptake inhibitors in clinical 
practice: tapering versus abrupt discontinuation. European Journal of 
Clinical Pharmacology 2005;61(4):303-7. doi: 
https://dx.doi.org/10.1007/s00228-005-0921-x 
Population was not described in terms of 
indication for antidepressant use. Study 
authors were contacted for details, but no 
response was received. 
47 Von Korff M, Katon W, Rutter C, et al. Effect on Disability Outcomes of a 
Depression Relapse Prevention Program. Psychosomatic Medicine 
2003;65(6):938-43. doi: 
http://dx.doi.org/10.1097/01.PSY.0000097336.95046.0C 
Intervention is not aimed at antidepressant 
reduction/discontinuation 
48 Wang HN, Wang XX, Zhang RG, et al. Repetitive transcranial magnetic 
stimulation for the prevention of depressive relapse/recurrence: An 
assessor blind, randomized controlled trial. Brain Stimulation 2017;10 
(2):507-08. doi: http://dx.doi.org/10.1016/j.brs.2017.01.482 
Outcomes for those patients who 
discontinued antidepressants were not 
reported 
49 Williams JMG, Crane C, Barnhofer T, et al. Mindfulness-based cognitive 
therapy for preventing relapse in recurrent depression: A randomized 
dismantling trial. Journal of Consulting and Clinical Psychology 
2014;82(2):275-86. doi: http://dx.doi.org/10.1037/a0035036 
Intervention is not aimed at antidepressant 
reduction/discontinuation 
50 Williams JMG, Russell IT, Crane C, et al. Staying well after depression: 
Trial design and protocol. BMC Psychiatry 2010;10 (no pagination)(23) 
doi: http://dx.doi.org/10.1186/1471-244X-10-23 
Intervention is not aimed at antidepressant 
reduction/discontinuation 
51 DRKS00006866. European Comparative Effectiveness Research on 
Internet-based Depression Treatment. 2014. 
Intervention is not aimed at antidepressant 
reduction/discontinuation 
52 NCT02747134. Combining Emotion Regulation and Mindfulness Skills for 
Preventing Depression Relapse. 2016. 
Intervention is not aimed at antidepressant 
reduction/discontinuation 
53 NCT02614326. MemFlex to Prevent Depressive Relapse. 2015. Intervention is not aimed at antidepressant 
reduction/discontinuation 
54 NCT02029963. Can Magnetic Brain Stimulation Help Prevent Relapse in 
Depression? 2014. 
Intervention is not aimed at antidepressant 
reduction/discontinuation 
55 NCT01807988. Internetbased Relapse Prevention for Partially Remitted 
Depression. 2013. 
Intervention is not aimed at antidepressant 
reduction/discontinuation 
56 NCT01619930. The Effects of Behavioral Activation and Physical Exercise 
on Depression. 2012. 
Intervention is not aimed at antidepressant 
reduction/discontinuation 
57 NCT00427128. Prozac Treatment of Major Depression: Discontinuation 
Study. 2007 
Intervention is not aimed at antidepressant 
reduction/discontinuation 
58 NCT00218764. Cognitive Therapy Versus Medication Treatment for 
Preventing Depression Relapse. 2005. 
Intervention is not aimed at antidepressant 
reduction/discontinuation 
59 NCT00183664. Cognitive Therapy for Treating Depression and 
Preventing Relapse. 2005. 
Intervention is not aimed at antidepressant 
reduction/discontinuation 
60 NCT00183560. Preventing Depression Relapse With Mindfulness-Based 
Cognitive Therapy. 2005. 
Intervention is not aimed at antidepressant 
reduction/discontinuation. 
61 NCT00057577. Prevention of Recurrence in Depression With Drugs and 
CT. 2003. 
Intervention is not aimed at antidepressant 
reduction/discontinuation 
62 JPRN-UMIN000005896. The effect of psychoeducation for the prevent 
from recurrence of major depression and familial expressed emotion. 
2011. 
Intervention is not aimed at antidepressant 
reduction/discontinuation 
63 JPRN-UMIN000005555. Family psychoeducation to prevent 
relapse/recurrent in the maintenance treatment of major depression: a 
randomized controlled trial. 2011. 
Intervention is not aimed at antidepressant 
reduction/discontinuation 
64 ISRCTN68246470. (Cost)effectiveness of a cognitive group prevention 
module for recurrent depression. 2006 
Intervention is not aimed at antidepressant 
reduction/discontinuation 
65 ISRCTN67561918. Psychotherapy for residual depression following 
initial treatment: effectiveness, relapse prevention and mechanisms of 
change. 2007. 
Intervention is not aimed at antidepressant 
reduction/discontinuation 
66 ISRCTN64953693. An integrative online self-help program (Deprexis®) 
versus waitlist control for adults with depressive symptoms. 2009. 
Intervention is not aimed at antidepressant 
reduction/discontinuation 
67 ISRCTN58808893. An SMS-assisted mindfulness-based intervention for 
relapse prevention in depression. 2014. 
Intervention is not aimed at antidepressant 
reduction/discontinuation 
68 ISRCTN44812125. Cognitive training as a facilitated self-help relapse 
prevention for depression. 2010 
Intervention is not aimed at antidepressant 
reduction/discontinuation 
69 ISRCTN15969819. Antidepressants to prevent relapse in depression. 
2015. 
Intervention is not aimed at antidepressant 
reduction/discontinuation 
70 ISRCTN12388725. E-COMPARED - internet-supported CBT for 
depression. 2015. 
 
Intervention is not aimed at antidepressant 
reduction/discontinuation 
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71 IRCT201111298253N1. Effect of psychological intervention on 
symptoms and preventing recurrence depression. 2012. 
Intervention is not aimed at antidepressant 
reduction/discontinuation 
72 ChiCTR-INR-16007984. Evaluation of mindfulness-based cognitive 
therapy (MBCT) in the treatment of depression curative effect and 
relapse prevention function: A randomized controlled study. 2016 
Intervention is not aimed at antidepressant 
reduction/discontinuation 
73 ACTRN12615001093572. Timely intervention: Efficacy of a depression 
symptom monitoring smartphone app to deliver psychological 
intervention at time of greatest need. 2015. 
Intervention is not aimed at antidepressant 
reduction/discontinuation 
74 ACTRN12613001204730. Opti-Med: A randomised controlled trial of 
deprescribing to optimise health outcomes for frail older people. 2013. 
Intervention is deprescribing of variety of 
medications  
75 ACTRN12611000370909. Deprescribing in frail older people: a 
randomised controlled trial. 2011 
Intervention is deprescribing of variety of 
medications 
76 ACTRN12608000613303. Maintenance antidepressants versus 
treatment cessation in the prevention of depression recurrence. 2008. 
Intervention is not aimed at antidepressant 
reduction/discontinuation 
77 ACTRN12607000166471. Effectiveness of Mindfulness-Based Cognitive 
Therapy Compared to Treatment-as-usual for Preventing Depressive 
Relapse in Subjects at Very High Risk. 2007. 
Intervention is not aimed at antidepressant 
reduction/discontinuation 
78 Intervention is not for antidepressant reduction/discontinuation Intervention is not aimed at antidepressant 
reduction/discontinuation 
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TABLE B: STUDY CHARACTERISTICS 
 
Depression (exclusion or non-reporting of anxiety co-morbidities) 
RCTs 
Study details Inclusion/exclusion criteria Participant characteristics 
Kahn 201438 
Country: USA 
Setting: 38 clinical research centres 
Study design: Phase 4 study with 24 week open label phase 
(n=480) followed by randomised discontinuation phase (n=361) 
Funding: Pfizer 
Full publication: Yes (journal article) 
Linked publications: Ninan 2015,39 NCT0105628940 
 
 
Inclusion criteria: Male and female adult outpatients, 18 years or 
older, with a primary diagnosis of single or recurrent MDD 
without psychotic features based on the criteria from the DSM-
IV, using the modified Mini International Neuropsychiatric 
Interview and depressive symptoms for at least 30 days before 
the screening visit and a 17-item Hamilton Rating Scale for 
Depression total score of 14 or greater at baseline. Patients who 
completed open label phase were then randomised to the 3 
study arms (continuation of treatment, tapered discontinuation, 
abrupt discontinuation) 
 
Exclusion criteria: Patients were excluded if they had a current 
diagnosis of an anxiety disorder that was considered to be 
primary; current psychoactive substance abuse or dependence; 
unstable hepatic, renal, pulmonary, cardiovascular (including 
uncontrolled hypertension, unstable angina, or recent 
myocardial infarction); ophthalmologic or neurologic disorder; or 
other clinically important medical disease (including 
uncontrolled diabetes) 
 
Age (years), mean (SD): INT: 47.9 (11.2); COMP 1: 47.8 (13.7), 
COMP 2: 46.7 (11.3) 
 
Female: INT: 74%; COMP 1: 68%; COMP 2: 67% 
 
Depression diagnosis: Major depressive disorder 
 
Antidepressant use: desvenlafaxine 50mg per day  
 
Duration of antidepressant use (weeks): 24 
Intervention details Comparator 1 details Comparator 2 details 
Name of intervention: Tapered discontinuation; N=140 
 
Description: desvenlafaxine 25 mg per day for 1 week followed 
by placebo for 3 weeks.  
 
Treatment duration (randomised phase): 1 week taper + 3 weeks 
placebo.  
 
Delivery: not reported 
 
Provider: not reported 
Name of intervention: Abrupt discontinuation; N=148 
 
Description: placebo for 4 weeks 
 
Treatment duration: 4 weeks 
 
Delivery: not reported 
 
Provider: not reported 
 
 
 
Name of intervention: Antidepressant continuation; N=73 
 
Description: continued desvenlafaxine 50 mg per day treatment 
for 4 weeks 
 
Treatment duration: not applicable 
 
Delivery: not reported 
 
Provider: not reported 
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Study details Inclusion/exclusion criteria Participant characteristics 
Klein 201742 
 
Country: Netherlands 
 
Setting: Mental health care sites  
 
Study design: Randomised controlled three-arm trial (only two 
arms (CT + taper versus m-ADM) were relevant as third arm was 
CT + mADM) 
 
Full publication: No (protocol and secondary analysis published 
only. Study ended 06/2017 and there was no trial report at the 
time of the review searches) 
 
Linked publications: Bockting 2011 (protocol),43 
ISRCTN1547214544 
 
Funding: Netherlands Organization for Health Research and 
Development (ZonMw), and Netherlands Organization for 
Scientific Research (NWO). 
Inclusion criteria: at least two previous depressive episodes in 
the past five years; currently in remission according to DSM-IV 
criteria for longer than 8 weeks and no longer than 2 years; have 
a current score of <10 in the 17 item Hamilton Rating Scale for 
Depression; have been remitted on antidepressant treatment; 
use AD at entry in the study (delivered in primary or secondary 
care) for at least 6 months 
 
Exclusion criteria: current mania or hypomania or a history of 
bipolar illness, any psychotic disorder (current and previous), 
organic brain damage, alcohol or drug dependency/abuse, 
predominant anxiety disorder 
 
The data for the Klein paper were drawn from a multi-centre trial 
(n = 238) i.e. the Bockting trial, and an extension of this trial with 
additional experience sampling (n = 51).The patient 
characteristics reported in the Klein paper are for 289 patients 
(i.e. the Bockting trial + the extension). It is unclear from the 
Klein paper who the patients in the extension were. The 
characteristics for the 289 patients were therefore not extracted. 
 
 
Intervention details Comparator details 
Name: Cognitive therapy with tapering of antidepressant (CT + taper); N=85 
 
Description: CT: 8 weekly group sessions. Therapists of the sites will be trained with a CT manual to promote treatment 
integrity. Patients will be encouraged to do homework as prescribed.  
Taper: GP’s and psychiatrists will be advised to taper antidepressants in 4 weeks to prevent withdrawal symptoms. In 
this arm patients will be asked for an intention to taper antidepressants. The patient is allowed to start antidepressants 
again at any time during the study.  
 
Treatment duration: CT: 8 weekly sessions 
Taper: 4 weeks 
 
Delivery: CT: group sessions,  
Taper: not reported 
 
Provider: CT: A team of clinical psychologists from the University of Groningen, Rotterdam University and Maastricht 
University, and psychiatrists from the University of Amsterdam and the University of Groningen.   
Taper: guided by GPs and psychiatrists. 
Name: continuation of maintenance antidepressant medication (m-ADM); N = 
not reported. Antidepressant use: 87.8% SSRI 
 
Description: GP’s and psychiatrists will be advised to continue antidepressant 
prescription at minimal required adequate used dosage (≥ 20 mg Fluoxetine 
equivalent; as recommended by national guidelines). Patients will be 
encouraged to use medications prescribed and doctors/ psychiatrists will be 
encouraged to prescribe therapeutic dosages, as well as discuss problems with 
adherence frequently. 
 
Treatment duration: not applicable 
 
Delivery: not reported 
 
Provider: GP’s and psychiatrists 
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Single arm trials 
Study details Inclusion/exclusion criteria Participant characteristics 
Huijbers 201634 
 
Country: Netherlands 
 
Setting: 12 secondary and tertiary psychiatric out-patient clinics 
 
Study design: Parallel two group non-inferiority RCT (only one arm 
(MBCT-TS) was relevant as second arm was MBCT+ maintenance 
antidepressant medication) 
 
Funding: The Netherlands Organization for Health Research and 
Development (ZonMW) 
 
Full publication: Yes (journal article) 
 
Linked publications: Huijbers 2012,35 Huijbers 2016,36 NCT0092898037 
Inclusion criteria: a history of at least three depressive episodes 
according to the DSM-IV; in full or partial remission, defined as 
not currently meeting the DSM-IV criteria for major depressive 
disorder; currently treated with antidepressants for at least 6 
months; 18 years of age or older; and Dutch speaking 
 
Exclusion criteria: bipolar disorder; any primary psychotic disorder 
(current and previous); clinically relevant neurological/somatic 
illness; current alcohol or drug dependency; high dosage of 
benzodiazepines (42 mg lorazepam equivalents daily); recent 
electroconvulsive therapy (53 months ago); previous MBCT and/or 
extensive meditation experience (for example retreats); current 
psychological treatment with a frequency of more than once per 3 
weeks; and inability to complete interviews and self-report 
questionnaires 
Age (years), mean (SD): INT: 50.7 (10.6)  
 
Female: INT: 72% 
 
Depression diagnosis at intake: In full remission (IDS-C 
≤11): INT: 70 (55%); In partial remission (IDS-C >11): INT: 
58 (45%) 
 
Antidepressant use:  SSRIs: INT: 92 (72%); TCAs: 26 (20%); 
Other (SNRI, mirtazapine, MAOI): 10 (8%) 
 
Duration of antidepressant use: not reported 
Intervention details 
Name of intervention: Mindfulness based cognitive therapy followed by guided discontinuation of maintenance antidepressant medication (MBC-TS), N=128 
 
Description: MBCT: MBCT largely based on the protocol by Segal, Williams & Teasdale with some adaptations. The intervention consisted of 8 weekly sessions of 2.5 hours (instead of 2 hours) and 1 day 
of silent practice between the sixth and seventh session. MBCT included formal meditation exercises, such as the body scan, sitting meditation, walking meditation and mindful movement as well as 
informal exercises, such as bringing present-moment awareness to everyday activities. Cognitive–behavioural techniques included education, monitoring and scheduling of activities, identification of 
negative automatic thoughts and devising a relapse prevention plan. Participants were encouraged to practice meditation at home for about an hour a day using CDs. 
TS: Patients were asked and recommended to withdraw gradually from their antidepressants over a period of 5 weeks, starting after the seventh session of MBCT. A protocol for medication tapering 
developed for this study by two experts in pharmacological treatment of major depressive disorder was provided. For discontinuation a minimum of 3 and a maximum of 12 consultations during the 
follow-up period were recommended.  
 
Treatment duration: MBCT: 8 consecutive weeks.  
TS: Patients were asked and recommended to withdraw gradually from their antidepressants over a period of 5 weeks starting after the seventh session of MBCT. Adherence to the study protocol was 
defined as attending four or more MBCT sessions, as in previous studies, and having fully discontinued maintenance antidepressant medication before the 6-month follow-up assessment (i.e. within 6 
months after baseline and within approximately 3–4 months after the last MBCT session) 
 
Delivery: MBCT: Group (8-12 participants). Groups were mixed comprising patients from both treatment groups as well as patients not included in the trial. 
TS: Face to face. 
 
Provider: MBCT: provided in 12 different centres with a total of 19 teachers and 111 MBCT courses. MBCT teachers were trained in the study protocol for MBCT during a 3-day training retreat in the 
beginning of the project, as well as at three subsequent training days every 6 months.  
TS: supervised by psychiatrists. 
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Study details Inclusion/exclusion criteria Participant characteristics 
Psaros 201451 
 
Country: USA 
 
Setting: Massachusetts General Hospital Center for 
Women's Mental Health in Boston or health care 
provider within the community 
 
Study design: Single arm trial 
 
Full publication: Yes (journal article) 
 
Linked publications: Psaros 201152 
 
Funding: not reported 
 
Inclusion criteria: aged 18 years or older; planning pregnancy or in the 
first trimester of pregnancy; independently decided to discontinue their 
antidepressant; were on treatment with a stable dosage of an 
antidepressant for at least 4 weeks at the time of the first visit; met 
stable depression remission criteria for at least 6 months and received a 
score of less than or equal to 9 on the Hamilton Rating Scale for 
Depression (HRSD); and had a history of a unipolar major depressive 
disorder. 
 
Exclusion criteria: demonstrated significant risk for self-harm or harm to 
others; had psychotic symptoms; met criteria for a primary diagnosis of 
schizophrenia, bipolar disorder, active eating disorder, dementia, 
delirium, or other cognitive disorder according to the Mini-International 
Neuropsychiatric Interview (MINI); had an active substance and or 
alcohol abuse disorder within 6 months before study entry; were 
currently using a mood stabilizer, antipsychotic, or antiepileptic; 
received CBT or interpersonal therapy within the last year; or had 
recently been diagnosed with a medical disorder that could mimic 
depressive symptoms (eg, hypothyroidism) 
Age (years), mean (SD): 34 (3.96) 
 
Female: 100% (1 patient pregnant at baseline) 
 
Depression diagnosis Major unipolar depression: n=11; Minor 
unipolar depression: n=1  
 
Antidepressant use: Bupropion: n=3; Sertraline: n=5; Fluoxetine: 
n=2; Citalopram: n=2 
 
Duration of antidepressant use: not reported 
Intervention details 
Name: cognitive behavioural therapy for the prevention of recurrence plus taper (CBT + taper); N=12 
 
Description: CBT: The CBT therapy used for this study followed the general principles of CBT with an emphasis on identifying and modifying maladaptive patterns of thinking and behaviour that may 
trigger or expose vulnerabilities for depression, particularly in the context of trying to conceive. For the acute treatment phase, visits included a baseline assessment, 12 sessions of CBT, and bimonthly 
independent assessments. The acute phase included 6 modules that focused on the following topics: presentation of the CBT model for depression, motivational interviewing, relaxation strategies, 
activity scheduling, cognitive restructuring, problem solving, and assertiveness. Participants could complete up to 3 optional monthly CBT booster sessions (with an additional 2 independent 
assessments) over the follow-up phase 
Taper: Drug taper schedules were determined at the baseline visit based on what was clinically appropriate for the medication and the preference of the participant. Typically, doses of medication were 
tapered at a rate of approximately 25% per week. The mean (SD) for the length of AD taper was 4.3 (2.53) weeks (range, 1–9 weeks). 
 
Treatment duration: acute phase (16 weeks), booster phase (12 weeks)  
 
Delivery: Face to face 
 
Provider: CBT sessions were conducted by a PhD level psychologist specifically trained in CBT. 
Taper: Drug taper schedules were determined at the baseline visit by participants in collaboration with staff physicians of the MGH Center for Women's Mental Health; 
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Observational studies 
Study details Inclusion/exclusion criteria Participant characteristics 
Himei 200654 
 
Country: Japan 
 
Setting: The clinical records of patients treated during the 
previous 5 years in the outpatient units of the Shindrome 
Abuyama Clinic and Shin-Abuyama Hospital, Osaka.  
 
Study design: Retrospective cohort 
 
Full publication: Yes (journal article) 
 
Linked publications: None 
 
Funding: None 
 
Inclusion criteria: had experienced a single episode of MDD 
diagnosed according to DSM-IV criteria; were given paroxetine 
as the only pharmacological treatment for their depression; had 
no comorbid substance dependence or abuse; and were no 
longer taking paroxetine for the treatment of depression. 
 
Exclusion criteria: patients who were even moderately clinically 
depressed, anxious, or hypomanic at the time of medication 
discontinuation as well as those whose rate of discontinuation 
was uncertain (22.3% of potential antidepressant-treated 
candidates). 
 
Age (years), mean (SD): OUTCOME 1: 40.5 (7.8); OUTCOME 2 : 
mean 37.2 (8.0) (statistical difference between groups) 
 
Female: OUTCOME 1: n=44%; OUTCOME 2: n=46% 
 
Depression: MDD diagnosed according to DSM IV criteria 
 
Antidepressant use: Paroxetine only.  
 
Maintenance dose, mean (SD): OUTCOME 1: 25.9mg/day (9.9); 
OUTCOME 2: 26.6mg/day (10.2) 
 
Duration of antidepressant use (months): OUTCOME 1: mean 9.2 
SD 4.1; OUTCOME 2: mean 9.9 SD 4.2 
Outcome1 details Outcome 2 details 
Name: Non discontinuation syndrome; N=344 (abrupt (n=53) or gradual (n=291) withdrawal of 
paroxetine (10mg reduction every 2 weeks)) 
 
Description: clinical records were examined to determine whether patients had been diagnosed as 
having experienced the discontinuation syndrome on stopping paroxetine. If they had been, this 
diagnosis was reconfirmed according to the criteria for the SSRI discontinuation syndrome 
proposed by Black et al. These criteria are: (i) the symptoms of the discontinuation syndrome 
appear within 3 days following cessation/ reduction in the dosage of paroxetine; (ii) two or more of 
the following symptoms are present: dizziness, lightheadedness, headache, nausea, paresthesia, 
loss of balance, irritability, agitation and insomnia; (iii) the symptoms cannot be explained as a 
relapse of depression or as any other medical condition; and (iv) the symptoms cause significant 
distress or impairment in social, occupational and other important areas of functioning. The 
patients had been followed-up to the end of treatment and were assessed for relapse of 
depression 4 and 8 weeks after medication was stopped 
 
Name: Discontinuation syndrome; N=41 (abrupt (n=27) or gradual (n=14) withdrawal of paroxetine 
(10mg reduction every 2 weeks)) 
 
Description: clinical records were examined to determine whether patients had been diagnosed as 
having experienced the discontinuation syndrome on stopping paroxetine. If they had been, this 
diagnosis was reconfirmed according to the criteria for the SSRI discontinuation syndrome 
proposed by Black et al. These criteria are: (i) the symptoms of the discontinuation syndrome 
appear within 3 days following cessation/ reduction in the dosage of paroxetine; (ii) two or more of 
the following symptoms are present: dizziness, lightheadedness, headache, nausea, paresthesia, 
loss of balance, irritability, agitation and insomnia; (iii) the symptoms cannot be explained as a 
relapse of depression or as any other medical condition; and (iv) the symptoms cause significant 
distress or impairment in social, occupational and other important areas of functioning. The 
patients had been followed-up to the end of treatment and were assessed for relapse of 
depression 4 and 8 weeks after medication was stopped 
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Depression and/ or anxiety disorders 
RCTs 
Study details Inclusion/exclusion criteria Participant characteristics 
Eveleigh 201527 
 
Country: Netherlands 
 
Setting: 45 general practices  
 
Study design: Two group cluster RCT 
 
Funding: Netherlands Organization for Health 
Research and Development (ZonMw) 
 
Full publication: Yes (PhD thesis) 
 
Linked publications: Muskens 2013,28 Eveleigh 
201429 
 
 
Inclusion criteria: Long-term antidepressant use (≥9 months). All 
antidepressants were included, except MAO-inhibitors; written informed 
consent.  
 
Exclusion criteria: Current treatment in a psychiatric in- or outpatient 
clinic; appropriate use of long-term antidepressants according to the 
Dutch guidelines for depressive and anxiety disorders (i.e. a history of 
recurrent depression (≥3 episodes) and/or a recurrent psychiatric 
disorder with at least two relapses after antidepressant discontinuation); 
history of psychosis, bipolar disorder, or obsessive compulsive disorder; 
current diagnosis of substance use disorder (excluding tobacco); non-
psychiatric indication for long-term antidepressant usage, e.g. 
neuropathic pain; hearing impairment and/or insufficient understanding 
of the Dutch language. 
 
Age (years), mean (SD): INT: 56 (12.9); COMP: 56 (14) 
Female: INT: 71%; COMP: 68% 
 
Life time psychiatric diagnosis: INT: n=53 (76%); COMP: n=48 (63%); 
Depression: INT: n=39 (57%); COMP: n=38 (46%); Panic disorder 
/agoraphobia: INT: 13 (19%); COMP: 13 (17%); Generalized anxiety 
disorder: INT: 22 (32%); COMP: 13 (17%); Social phobia: INT: 16 (23%); 
COMP: 20 (26%) 
 
Antidepressant use: SSRI: INT: n=57 (81.4%); COMP: n=50 (65.8%); 
SNRI: INT: n=7 (10%); COMP: n=11 (14.5%); Other (non TCA): INT: n=2 
(2.9%); COMP: n=10 (13.2%); TCA: INT: n=4 (5.7%); COMP: n=5 (6.6%) 
 
Duration of antidepressant use (years), median (range):  INT: 8.0 (1 to 
48); COMP: 9.5 (1 to 56) 
Intervention details Comparator details 
Name: Letter to GP disclosing patient does not meet the criteria for a depressive or anxiety disorder in the past six 
months combined with  a (patient-tailored) treatment recommendation to discontinue; N = 22 practices (70 
patients)  
 
Description: The GP receives a letter stating that the patient does not meet the criteria for a depressive or anxiety 
disorder in the past six months. In addition, he or she receives an information sheet with current guidelines on 
antidepressant tapering and information about the discontinuation syndrome, including a detailed scheme for 
tapering for each patient. Duration of tapering was primarily based on the dosage and the half-life of the different 
antidepressants. No treatment restrictions are imposed on GP or patient in case of relapse or onset of a new 
psychiatric disorder after discontinuation.  
 
Treatment duration: Patient consultation with GP to discuss recommendation was approximately 3 months from 
baseline 
 
Delivery: Letter to GP + face to face discussion of recommendation between GP and patient 
 
Provider: GP 
Name: Usual care; N = 23 practices (76 patients) 
 
Description: GPs were unaware which patients participated in this study and 
continued usual care. The control condition will consisted of usual care and did not 
impose restrictions on GPs to deliver care or to refer to specialised mental health 
care, including the continuation or discontinuation of psychotropic drugs.  
 
Treatment duration: not applicable 
 
Delivery: Face to face 
 
Provider:  GP 
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Study details Inclusion/exclusion criteria Participant characteristics 
Fava 199415 
 
Country: Italy  
 
Setting: Outpatients referred to and treated in the Affective Disorders 
Program of the University of Bologna School of Medicine in Italy.  
 
Study design: Parallel two group RCT 
 
Funding: Partially supported by Ministero Universita e Ricerca 
Scientifica e Tecnlogica; Consiglio Nazionale delle Ricerche; and Mental 
Health Project, Istituto Superiore di Sanità, Rome 
 
Full publication: Yes (journal article) 
 
Linked publications: Fava 1996,30 Fava 199831 
Inclusion criteria: A current diagnosis of primary major 
depressive disorder according to the Research Diagnostic 
Criteria (RDC); successful response to 3 to 5 month’s full 
antidepressant treatment administered by the same 
psychiatrist according to standardized protocol. After drug 
treatment, rated as “better" or “much better" according to 
Kellner's global rating scale of improvement, in full remission 
and in stage 3 of primary unipolar depression.   
 
Exclusion criteria: history of manic, hypomanic, or 
cyclothymic features; history of active drug or alcohol abuse 
or dependence; history of personality disorder according to 
DSM-III-R criteria; history of antecedent dysthymia, active 
medical illness; no evidence of depressed mood after 
treatment, absence of residual symptoms. 
 
Age (years), mean (SD): INT: 43 (2.3); COMP: 48.5 (3.3) 
 
Female: INT: 60%; COMP: 75%  
 
Depression - residual symptoms after successful treatment:  
All patients reported residual symptoms, with a mean of 2.7 
(1.2) per patient. The most frequently reported symptoms 
were: generalized anxiety (73% of patients), somatic anxiety 
(55%), and irritability (40%). 
 
Antidepressant use: Amitriptyline: INT: n=7 (35%); COMP: 
n=12 (60%); Desipramine: INT: n=6 (30%); COMP: n=2 (10%); 
Imipramine: INT: n=5 (25%); COMP: n=4 (20%); Mianserin: 
INT: n=2 (10%); COMP: n=2 (10%); 
 
Duration of antidepressant use (months): 3 to 5 
Intervention details Comparator details 
Name: Cognitive behavioural therapy + tapering (CBT + taper); N=21 (tapering was not feasible for 
n=1, and they were excluded from further participation in the study, but included in analysis) 
 
Description: Treatment consisted of 10 40-minute sessions once every other week. Antidepressant 
drugs were tapered at the rate of 25 mg of amitriptyline or its equivalent every other week, and 
then they were withdrawn completely. Cognitive therapy was conducted as described by Beck, and 
included strategies and techniques designed to help depressed patients correct their distorted 
views and maladaptive beliefs. Whenever appropriate, as in the case of residual symptoms related 
to anxiety, exposure strategies were planned with the patient. Patients already on benzodiazepines 
were allowed to continue to do so.  
 
Treatment duration: 20 weeks (10 sessions, 1 every other week) 
 
Delivery: Face to face 
 
Provider: 1 psychiatrist, with extensive experience in affective disorders and cognitive behavioural 
psychotherapy, who had initially treated the patients. The psychiatrist performed treatment in 
both groups. 
Name: Clinical management + tapering (CM +; N=22 (tapering was not feasible for n=2, and they 
were excluded from further participation in the study, but included in analysis) 
 
Description: Treatment consisted of 10 40-minute sessions once every other week. Antidepressant 
drugs were tapered at the rate of 25 mg of amitriptyline or its equivalent every other week, and 
then they were withdrawn completely. Clinical management consisted of monitoring medication 
tapering, reviewing the patient's clinical status, and providing the patient with support and advice 
if necessary. Interventions such as exposure strategies, diary work and cognitive restructuring were 
proscribed. Patients already on benzodiazepines were allowed to continue to do so. 
 
Treatment duration: 20 weeks (10 sessions, 1 every other week) 
 
Delivery: Face to face 
 
Provider: 1 psychiatrist, with extensive experience in affective disorders and cognitive behavioural 
psychotherapy, who had initially treated the patients. The psychiatrist performed treatment in 
both groups. 
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Study details Inclusion/exclusion criteria Participant characteristics 
Fava 199832 
 
Country: Italy 
 
Setting: Outpatients referred to and treated in the 
Affective Disorders Program of the University of 
Bologna School of Medicine in Italy. 
 
Study design: Parallel two group RCT 
 
Funding: Partially supported by the "Mental Health 
Project," Istituto Superiore di Sanita and the 
"Ministero dell Universita e della Ricerca 
Scientifica e Tecnologica 
 
Full publication: Yes (journal article) 
 
Linked publications: Fava 200433 
Inclusion criteria: A current diagnosis of major depressive disorder according to the 
RDC for a Selected Group of Functional Disorders; 3 or more episodes of 
depression, with the immediately preceding episode being no more than 2 1/2 
years before the onset of the present episode5; a minimum 10-week remission 
according to RDC (≤2 symptoms present to no more than a mild degree with 
absence of functional impairment) between the index episode and the immediately 
preceding episode; a minimum global severity score of 7 for the current episode of 
depression; and successful response to antidepressant drugs administered by 2 
psychiatrists according to a standardized protocol (use of TCAs, with gradual 
increases in dosages. Patients who could not tolerate TCAs were switched to SSRIs). 
After drug treatment, rated as “better" or “much better" according to global rating 
scale of improvement, in full remission and in stage 3 of primary unipolar 
depression.   
 
Exclusion criteria: a history of manic, hypomanic, or cyclothymic features (i.e. 
bipolar depression); a history of active drug or alcohol abuse or dependence or of 
personality disorder according to DSM-IV criteria; a history of antecedent 
dysthymia; or active medical illness 
Age (years), mean (SD): INT: 45.1 (10.3); COMP: 48.7 (12.1) 
 
Female: INT: 55%; COMP: 65% 
 
Depression – Pre-intervention scores for the Clinical 
Interview for Depression (CID), mean (SD): INT 30.8, SD (3.3); 
COMP 29.7 (3.9) 
 
Comorbidities: Generalized anxiety disorder: INT: n=6 (30%); 
COMP: n=4 (20%); Agoraphobia: INT: n=3 (15%); COMP: n=3 
(15%); Social phobia: INT: n=0 (0%), COMP: n=1 (5%)  
 
Antidepressant use:  Amitriptyline: INT: n=7 (35%); COMP: 
n=7 (35%); Imipramine: INT: n= 5 (25%); COMP: n=5 (25%); 
Desipramine: INT: n=5 (25%); COMP: n=6 (30%); Fluoxetine: 
INT: n=2 (10%); COMP: n=2 (10%); Sertraline: INT: n=1 (5%); 
COMP: n=0 (0%) 
 
Duration of antidepressant use (months): 3 to 5 
Intervention details Comparator details 
Name: Cognitive behavioural therapy + tapering (CBT + taper); N=23 (tapering was not feasible for n=3 and they 
were excluded from further participation in the study, but included in analysis) 
 
Description: 10 30-minute sessions once every other week. Antidepressant drug use was tapered at the rate of 25 
mg of amitriptyline hydrochloride or its equivalent every other week, and then the drugs were withdrawn 
completely (in the last 2 sessions, all patients were drug free). Cognitive behavioural treatment consisted of the 
following 3 main ingredients: (1) CBT of residual symptoms of major depression. Cognitive therapy was 
conducted as described by Beck et al., (2) Lifestyle modification. Patients were instructed that depression is 
merely the consequence of a maladaptive lifestyle, which does not take life stress, interpersonal friction, 
excessive work, and inadequate rest into proper account The strategies used technically derived from lifestyle 
modification approaches that were effective in clinical cardiological studies. (3) Well-being therapy. In the last 2 
or 3 sessions, a psychotherapeutic strategy for enhancing well-being was used based on Ryff and Singer's 
conceptual model of well-being as the result of self-acceptance, positive relations with others, autonomy, 
environmental mastery, purpose in life, and personal growth. A few patients were taking benzodiazepines at low 
doses and continued to do so throughout the study. 
 
Treatment duration: 20 weeks (10 sessions, 1 every other week) 
 
Delivery: Face to Face 
 
Provider: 1 psychiatrist, who performed all treatments in both groups. 
Name: Clinical management + tapering (CM + taper); N=22 (tapering was not feasible 
for n=2, and they were excluded from further participation in the study, but included 
in analysis) 
Description: 10 30-minute sessions once every other week. Antidepressant drug use 
was tapered at the rate of 25 mg of amitriptyline hydrochloride or its equivalent 
every other week, and then the drugs were withdrawn completely (in the last 2 
sessions, all patients were drug free). Clinical management consisted of monitoring 
medication tapering, reviewing the patient's clinical status, and providing the patient 
with support and advice if necessary. Specific interventions such as exposure 
strategies, diary work, and cognitive restructuring were proscribed. The patient was 
encouraged to share the main events that took place in the previous 2 weeks. A few 
patients were taking benzodiazepines at low doses and continued to do so 
throughout the study. 
 
Treatment duration: 20 weeks (10 sessions, 1 every other week) 
 
Delivery: Face to Face 
 
Provider: 1 psychiatrist, who performed all treatments in both groups 
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Study details Inclusion/exclusion criteria Participant characteristics 
Kuyken 200816 
 
Country: UK 
 
Setting: Primary care settings across a range of urban and rural locations in Devon. 
Patients were identified from computerised practice databases 
 
Study design: Parallel two group RCT, stratified by symptomatic status (HRSD ≥ 8) 
 
Funding: UK Medical Research Council 
 
Full publication: Yes (journal article) 
 
Linked publications: ISRCTN12720810 200641 
Inclusion criteria: Patients aged 18 years or older; history 
of three or more previous episodes of depression meeting 
DSM IV criteria for depression, treated with therapeutic 
dose of antidepressants over the last 6 months and 
currently in full or partial remission. 
 
Exclusion criteria: Comorbid diagnoses of current 
substance dependence; organic brain damage; 
current/past psychosis; bipolar disorder; persistent 
antisocial behaviour; persistent self-injury requiring 
clinical management/ therapy; unable to engage with 
MBCT for physical, practical, or other reasons (e.g., very 
disabling physical problem, unable to comprehend 
materials); and formal concurrent psychotherapy  
 
Age (years), mean (SD): INT: 48.95 (10.55); COMP: 
49.37 (11.84)  
 
Female: INT: 77%; COMP: 76% 
 
Depression diagnosis at intake: In full remission: INT: 
69%; COMP: 66%; In partial remission: INT: 31%; 
COMP: 34%  
 
Number of comorbid DSM-IV Axis I psychiatric 
diagnoses, mean (SD): INT: 0.83 (0.96); COMP: 1.04 
(1.11) 
 
Antidepressant use: SSRIs: 58%; TCAs: 22%; 
Combination: 20% 
 
Duration of antidepressant use (months): ≥ 6 
Intervention details Comparator details 
Name: Mindfulness based cognitive therapy + support to taper/discontinue antidepressants (MBCT-TS); N=61 
 
Description: MBCT: 2 hour sessions per week. Sessions content followed treatment protocol (Segal, Williams, & Teasdale, 
2002) and included guided mindfulness practices (i.e., body scan, sitting meditation, yoga); inquiry into patients’ 
experience of these practices; review of weekly homework (i.e., 40 minutes of mindfulness practice per day and 
generalization of session learning); and teaching/discussion of cognitive– behavioural skills. An adequate dose of MBCT 
was defined as participation in at least four of the eight MBCT group sessions.  
TS: Study team provided guideline information to physicians and patients about typical tapering/discontinuation regimes 
and possible withdrawal effects. Patients and physicians prompted to begin discussing a tapering/discontinuation regime 
after 4–5 weeks of the MBCT groups. At the end of the MBCT groups, they were reminded to ensure a 
tapering/discontinuation regime was in place. 
 
Treatment duration: MBCT: 8 consecutive weeks, followed by four follow-up sessions in the following year.  
TS: The research team asked that patients consider tapering/discontinuing their medication as soon following MBCT as 
they deemed appropriate and within 6 months of the MBCT group ending. 
 
Delivery: Primary care settings with MBCT groups of 9–15 patients 
 
Provider: MBCT: clinical psychologist or occupational therapist. Both therapists had undergone a training program taught 
by one of the developers of MBCT, had experience of running at least two supervised pilot groups, and had an ongoing 
personal mindfulness practice.  
TS: Tapering/discontinuation regimes determined by physicians and patients.  
Name: Maintenance antidepressant medication (m-ADM); N=62 
 
Description: maintenance of the antidepressant medication treatment that 
was an inclusion criterion for the study. During the maintenance phase, 
physicians were asked to manage m-ADM in line with standard clinical 
practice and the British National Formulary. Protocol adherence was defined 
as continuing to take m-ADM at a therapeutic maintenance dose for the 
duration of the trial. Changes in medication sometimes occurred during the 
maintenance treatment stage, but physicians and patients were asked to 
ensure the dose remained within therapeutic limits. 
 
Treatment duration: duration of trial (15 months) 
 
Delivery: GPs were asked to meet with patients regularly to review their 
medication treatment. 
 
Provider: GP 
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Study details Inclusion/exclusion criteria Participant characteristics 
Kuyken 201517 
 
Country: UK 
 
Setting: General practices in urban and rural settings in 
Bristol, Exeter and East, North, and South Devon  
 
Study design: Parallel two group RCT, stratified by 
locality and symptomatic status (GRID HAMD ≥ 8) 
 
Funding: National Institute for Health Research  
 
Full publication: Yes (HTA report) 
 
Linked publications:, Kuyken 2010,45 Kuyken 2014,46 
Kuyken 2015,47 Anonymous 2016,48 ISRCTN2666665449 
Inclusion criteria: Patients aged 18 years or older, with a diagnosis of recurrent 
major depressive disorder in full or partial remission according to the DSM-IV, a 
history of  three or more previous major depressive episodes in which 
depression was the primary disorder and it was not secondary to substance 
abuse, bereavement or a general medical condition, were on a therapeutic dose 
of ADM, and were open either to continue taking antidepressants for 2 years or 
to take part in a MBCT class and consider stopping their ADM. 
 
Exclusion criteria: Depressed, as assessed using the Structured Clinical Interview 
for DSM-IV (SCID); had a comorbid diagnosis of current substance abuse 
(patients with previous substance abuse were eligible for inclusion as long as 
they were in sustained full remission); organic brain damage; current/past 
psychosis, including bipolar disorder; displayed persistent antisocial behaviour; 
engaged in persistent self-injury that required clinical management/therapy; 
were undergoing formal concurrent psychotherapy. 
Age (years), mean (SD): INT: 50 (12); COMP: 49 (13) 
 
Female: INT: 71%; COMP: 82% 
 
Depression diagnosis at intake:  
Asymptomatic: INT: 77%; COMP: 76% 
Symptomatic: INT: 23%; COMP: 24% 
 
No. of comorbid DSM-IV Axis I psychiatric diagnoses, 
mean (SD): INT: 0.5 (0.9); COMP: 0.7 (0.9) 
 
Antidepressant use (weeks prescribed over 24 month 
follow up period): SSRIs: 21642.5; SNRIs: 2690; TCAs: 
2586, Mirtazapine: 1541; Agomelatine: 64; Others: 32; 
Flupentixol: 24; Moclobemide: 14 
Duration of antidepressant use: not reported 
Intervention details Comparator details 
Name: Mindfulness based cognitive therapy + support to taper/discontinue antidepressants (MBCT-TS); N=212 
 
Description: MBCT: 2.25 hour sessions per week. Session content included guided mindfulness practices (i.e. body scan, sitting 
meditation, movement); inquiry into participants’ experience of these practices; weekly review of home practice (i.e. 40 minutes of 
mindfulness practice per day with the guidance of a CD, bringing mindfulness into everyday life); and teaching of/dialogue around 
cognitive–behavioural skills. The original MBCT manual was adapted to include more work on developing a relapse/recurrence 
signature and response plan that explicitly included participants considering reduction/discontinuation of m-ADM. There were an 
additional four group reunion sessions during the first year of follow-up to provide ongoing support and rehearse the key 
components of the interventions. An adequate dose of MBCT was defined as participation in at least four of the eight MBCT group 
sessions. 
TS: Letters signed by the chief investigator and trial GP were sent to each participant’s GP, copied to the participant, prompting the 
GP to have a discussion with the participant about a suitable tapering/discontinuation regime after 4–5 weeks of the MBCT-TS 
group. At the end of the MBCT-TS group another letter was sent reminding the GP to ensure that a tapering/discontinuation regime 
was in place. Study team wrote to participant and their GP after each follow-up reminding them that the trial was seeking to 
compare staying on antidepressants with taking part in mindfulness classes and stopping ADM. Participants who experienced a 
significant deterioration following tapering were encouraged to use the skills developed as part of the MBCT treatment. Actual 
timeline and regime used to taper were determined by physicians and participants Use of pain killers and sleeping tablets was 
allowed ( % usage was the same in both study arms). 
 
Treatment duration: 8 consecutive weeks, followed by four follow-up sessions in the following year. 
 
Delivery: one-to-one orientation session with the therapist followed by group sessions. 
 
Provider: 4 MBCT therapists (2 clinical psychologists, 2 occupational therapists) with post-qualification experience averaging 19 
years, extensive training and experience in leading MBCT groups (min. 4 years). TS: GPs 
Name: Maintenance antidepressant medication (m-ADM); N=212 
 
Description: During the maintenance phase, physicians were asked 
to manage m-ADM in line with standard clinical practice and the 
British National Formulary (BNF). Trial GPs and psychiatrist 
provided materials for all participants and participating GPs on m-
ADM and ongoing support as required. Participants were 
encouraged to adhere to medication for the full length of the trial 
by sending them letters signed by the chief investigator and their 
GP after each follow-up, reminding them that the trial was seeking 
to compare staying on antidepressants for 2 years with taking part 
in mindfulness classes and stopping ADM. Changes in medication 
sometimes occurred during the maintenance treatment stage but 
physicians and participants were asked to ensure that the dose 
remained within therapeutic limits. Use of pain killers and sleeping 
tablets was allowed (% usage was the same in both study arms. 
 
Treatment duration: 24 months 
 
Delivery: GPs were asked to meet with patients regularly to review 
their medication treatment. 
 
Provider: GPs 
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Single arm trials 
Study details Inclusion/exclusion criteria Participant characteristics 
Johnson 201250 
 
Country: Scotland 
 
Setting:4 CHCPs containing urban general 
practices in most deprived areas 
 
Study design: Single arm intervention 
 
Funding: HCP Local Enhanced Service and 
NHS GG&C Mental Health Collaborative 
monies. 
 
Full publication: Yes (journal article) 
 
Linked publications: None 
 
Inclusion criteria: Patients prescribed the same antidepressant for ≥2 years were 
identified by community health and care partnerships (CHCPs) support staff 
using a data extraction tool specifically designed, developed and piloted to 
identify this patient group from individual General Practice Administration 
System Scotland systems. This tool identified patients prescribed an 
antidepressant within the previous 3 months and patients prescribed the same 
antidepressant for 2 years or more. This duration was chosen as current 
guidelines recommend up to 2 years antidepressant treatment for those at risk 
of relapse. Amitriptyline was excluded from the search due to its non-mental 
health uses. Duloxetine was included as an earlier audit of the data found that 
prescriptions for managing conditions other than depression were sparse. 
 
Exclusion criteria: Patients were excluded if aged <18 years, under regular 
psychiatric care, had a GP face-to-face antidepressant review within the 
preceding 6 months, or were on the severe mental illness register (practices 
review this group as part of the Quality Outcomes Framework [QOF]) 
 
Age (years), mean (SD): 54.4 (13.4) 
 
Female (Demographic data were available for 94.4% (2691/2849) 
patients reviewed): 1975/2691  
 
Indication for antidepressant use (1929/284 (67.7%) had 
antidepressant indication recorded): Depression: 65.0%, Mixed anxiety 
depression: 22%; Anxiety disorder: 10%; Other mental health 1, 
General medical; 1.5%.   
 
Antidepressant use: Fluoxetine: 26.8%; Citalopram: 25.8%; Paroxetine: 
8.7%; Venlafaxine: 7.3%; Trazodone: 6.7%; Sertraline: 6.2%; 
Mirtazapine: 6.1%; Dosulepin: 5.0%; Escitalopram: 2.4%; Lofepramine: 
2.1%; Duloxetine:1.1%; Other: 1.7% 
 
Duration of antidepressant use (years): mean 5.5, SD 3.0, range 2.0 to 
24.8  
Intervention details 
Name of intervention: GP face to face review with patient of clinical condition and medication; N=2849 
 
Description: Practices were asked to review and submit forms for a proportion of all registered patients (equivalent to 30 per 4000 patients). Other than exclusion criteria, GPs were not provided with 
guidance or a sampling framework from which to select patients, therefore GPs were allowed to prioritise patients for review, permitting flexibility to pragmatically select patients they felt may benefit 
most, at the expense of introducing selection bias into the study. At review GPs completed a standardised review form recording: date of review, CHCP, practice, name of antidepressant(s), daily dose, 
changes in antidepressant therapy and any onward referral. Subsequent amendments were made to capture patients’ age, sex, GP-defined indication, and duration of current antidepressant for CHCP-2 
to 4. 
 
Treatment duration: All practices in the four CHCPs reviewed patients once and CHCP-1 followed-up with a second review within 3 months of the first. 
 
Delivery: Face to face 
 
Provider: GP 
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Observational studies 
Study details Inclusion/exclusion criteria Participant characteristics 
Baldessarini 201053 
 
Country: Italy 
 
Setting: the Lucio Bini Mood Disorders Center 
affiliated with the University of Cagliari in 
Sardinia 
 
Study design: Retrospective cohort 
 
Full publication: Yes (journal article) 
 
Linked publications: No  
 
Funding: Supported in part by the NIH; the Lucio 
Bini Private Donors Mood Disorders Research 
Fund; the Bruce J. Anderson Foundation and the 
McLean Private Donors Psychopharmacology 
Research Fund.  
 
Inclusion criteria: consecutive patients who met the following criteria: diagnosed 
clinically with DSM-based recurrent major depressive disorder, bipolar I or II 
disorder, or panic disorder; received a tricyclic antidepressant (or the tricyclic-like 
tetracyclics maprotiline and mianserin), a modern antidepressant (serotonin 
reuptake inhibitors or bupropion, duloxetine, or venlafaxine), or more than one 
antidepressant, with or without a mood stabilizer, following standard clinical 
practices regarding drug selection and dosing in the study community; recovered 
from an antidepressant-treated index episode of a major depression or panic 
disorder, based on clinical euthymia and a score ≤7 on the Hamilton Depression 
Rating Scale sustained for at least 30 days (including patients with panic disorder 
evaluated with the same rating scale for consistency); discontinued medication 
electively for clinical or personal reasons over a known period of time, allowing 
categorization into groups based on rapid (1–7 days) or gradual (≥2 weeks) 
discontinuation; remained clinically stable or euthymic for at least 1 week after 
discontinuing treatment; and remained under prospective observation for at least 1 
year, during initial treatment and through a first new episode of major depression or 
panic disorder that met DSM-IV diagnostic criteria at clinical assessment. Follow-up 
was censored at 100 months.  
 
Exclusion criteria: patients who were even moderately clinically depressed, anxious, 
or hypomanic at the time of medication discontinuation as well as those whose rate 
of discontinuation was uncertain (22.3% of potential antidepressant-treated 
candidates). 
Age (years), mean (SD): EXP 1: 44.1 (15.4); EXP 2: 39.5, (14.5) 
(Note: Data not reported by diagnosis i.e. data for MDD, 
panic disorder, BP I and BP II patients were combined) 
 
Female: EXP 1: 69%; EXP 2: 61.7% (Note: Data not reported 
by diagnosis i.e. data for MDD, panic disorder, BP I and BP II 
patients were combined) 
 
Psychiatric diagnosis: Recurrent major depressive disorder 
EXP 1: n=118 (56.2%); EXP 2: 106 (56.4%); Panic disorder: 
EXP 1: n=38 (18.1%); EXP 2: 37 (19.7%); Bipolar II disorder: 
EXP 1: 33 (15.7%); EXP 2: 29 (15.4%); Bipolar I disorder: EXP 
1: 21 (10.0%); EXP 2: 16 (8.5%)    
 
Antidepressant use: TCA and tetracyclics (amprotiline and 
mianserin): n=249 (62.6%), Modern antidepressants (SSRI, 
bupropion, duloxetine or venlafaxine): n=149 (37.4%), Mood 
stabilisers: n=125 (31.5%), Sedatives: n= 255 (64.1%) (Note: 
Data not reported by diagnosis i.e. data for MDD, panic 
disorder, BP I and BP II patients were combined) 
 
Duration of antidepressant use: not reported 
Exposure 1 Exposure 2 
Name: Gradual discontinuation; N=210 
 
Description: Discontinuation ≥  2 weeks (none of the patients tapered off in the 8 to 14 day range) 
 
Treatment duration: not reported  
 
Delivery: not reported 
 
Provider: Decisions to discontinue treatment were clinical, not experimental; they were decided by 
the patient in 80.7% of cases and at the advice of the prescribing physician in 19.3% of cases. 
Gradual discontinuation was slightly more prevalent than rapid (53% compared with 47% of cases),  
Among study patients, adjunctive psychotropic medications were continued unchanged after 
discontinuation of antidepressants.  
Name: Rapid discontinuation ; N=188 
 
Description: discontinuation over 1- 7 days 
 
Treatment duration: not reported 
 
Delivery: not reported 
 
Provider:  Decisions to discontinue treatment were clinical, not experimental; they were decided by 
the patient in 80.7% of cases and at the advice of the prescribing physician in 19.3% of cases. 
Stopping abruptly or rapidly was almost always the patient’s decision (94.1% of discontinuations) 
Among study patients, adjunctive psychotropic medications were continued unchanged after 
discontinuation of antidepressants.  
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Ongoing studies 
Study details Inclusion/exclusion criteria 
Molenaar 201655 
 
Country: Netherlands 
 
Setting: Not reported 
 
Study design: Pragmatic multi-centre randomized controlled non-inferiority trial 
 
Full publication: Protocol is published as a journal article 
 
Linked publications: Lambregtse-Van Den Berg 201556 
 
Funding: Netherlands Organization for Health Research and Development and Erasmus Medical Centre, Department of 
Psychiatry. 
Inclusion criteria: Women who are less than 16 weeks pregnant and use a 
SSRI primarily for depressive disorder, and are currently at least in 
remission or recovered, 
 
Exclusion criteria: multiple pregnancy, as these women have a markedly 
increased obstetric risk, thereby threatening the homogeneity of the study 
population and thus potentially complicate the statistical analysis; 
insufficient proficiency in Dutch or English, since intervention is not yet 
available in other languages; severe medical conditions, such as oncology-
related conditions or conditions that need urgent medical interventions, 
which involve treatment decisions overriding research participation; 
current mania or hypomania or a history of bipolar illness, suicidality and 
serious self-harm, any psychotic disorder (current and previous), current 
alcohol or drug misuse, predominant anxiety disorders and personality 
disorders that require psychotherapeutic treatment for more than 2 
sessions a month. 
Intervention details Comparator details 
Name: Guided tapering of SSRI according to protocol with preventive cognitive therapy (STOP) 
 
Description: Taper: Women will be referred to a psychiatrist trained in guiding tapering of SSRIs during pregnancy. They will 
plan and carry out SSRI discontinuation using an expert-based discontinuation protocol. The aim is to taper the use of SSRIs 
within four weeks, depending on patient preferences and on drug characteristics (e.g., half-life in the body).  
Preventive cognitive therapy: Trained psychologists will provide preventive cognitive therapy. This psychological 
intervention has proven to be effective in relapse prevention and the current manual was evaluated in previous studies. 
The preventive psychological intervention consists of a minimum of eight weekly VSee sessions. These sessions are led by 
professional psychologists trained in cognitive behavioural therapy and may occur at any time of the day. The focus of the 
sessions is on identifying and teaching the participants to challenge dysfunctional beliefs, enhance recall of positive feelings 
and cognitions and a personal prevention plan is developed in which it is specified how the participant can prevent a 
depressive episode in the future. For each session the participant will receive some assignments of approximately 10 min 
per day. There are no restrictions on the use of medication like sleeping pills, paracetamol, and mild tranquillizers. 
 
Treatment duration: Taper: aim is to taper the use of SSRIs within four weeks, depending on patient preferences and on 
drug characteristics (e.g., half-life in the body).  
CT: The preventive psychological intervention consists of a minimum of eight weekly VSee sessions 
 
Delivery: CT: The intervention will be applied through VSee (http:// www.vsee.com), a HIPAA-compliant telehealth app 
 
Provider: Taper: psychiatrist trained in guiding tapering of SSRIs during pregnancy  
CT: Sessions are led by professional psychologists trained in cognitive behavioural therapy 
Name: Continuation of SSRIs - usual care (GO) 
 
Description: Women instructed to consult their doctor as they regularly do, 
in line with the pragmatic nature of the study. All the care that is provided 
will be monitored. 
 
Treatment duration: not reported 
 
Delivery: usual care 
 
Provider: usual care 
 
Study details Inclusion/exclusion criteria 
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NCT02661828_201657 
 
Country: USA 
 
Setting: Not reported 
 
Study design: RCT, open label 
 
Full publication: Clinical trial.gov entry 
 
Linked publications: None 
 
Funding: Emory University 
 
Inclusion criteria: Age 18-75 years; currently taking an FDA-approved antidepressant for at least 
four weeks on the list of approved medications: SSRIs (citalopram, escitalopram, fluoxetine, 
fluvoxamine, paroxetine, sertraline, vilazodone or vortioxetine), SNRIs (desvenlafaxine, duloxetine, 
levomilnacipran, venlafaxine) and other classes (amitriptyline, bupropion, desipramine, doxepin, 
mirtazapine, nefazodone, nortriptyline, phenelzine, selegiline, or tranylcypromine). Clomipramine, 
a tricyclic antidepressant approved for the treatment of OCD, will also be included, but will be 
classed as an SSRI for this study because inhibition of the serotonin transporter is its primary 
therapeutic mechanism; no longer wishes to take the antidepressant medication they are currently 
prescribed, due to one of the following reasons: 1) ineffective for symptoms; 2) intolerable side 
effect; 3) improvement of their illness for sufficient duration that it is clinically appropriate to 
consider  tapering the medication; primary psychiatric diagnosis of major depressive disorder, an 
anxiety disorder, OCD, or PTSD and; ability to read and understand English language. 
Exclusion criteria: Has met criteria at any time during their life for a primary psychotic disorder (e.g. 
schizophrenia), or dementia; meets criteria for DSM-5-defined substance use disorder within three 
months of the screening visit; currently taking two or more antidepressants; presents with a 
clinically significant suicide risk, as assessed by a study physician; presence of any unstable or 
central nervous system-related medical illness that would interfere with cognition or participation; 
women who are currently pregnant or lactating, or plan to become pregnant during the study. 
Intervention details Comparator details 
Name: Two-Week Antidepressant Taper Regimen 
 
Description: Two-Week Taper Regimen to discontinue medication. Days 1-7: 50% of baseline 
antidepressant dose taken; Days 8-14: 25% of baseline antidepressant dose taken; Day 15: Stop 
antidepressant. 
 
Treatment duration: 2 weeks 
 
Delivery: not reported 
 
Provider: not reported 
Name: One-Week Antidepressant Taper Regimen 
 
Description: One-Week Taper Regimen to discontinue medication. Days 1-3: 50% of baseline 
antidepressant dose taken; Days 4-7: 25% of baseline antidepressant dose taken; Day 8: Stop 
antidepressant. 
 
Treatment duration: 1 week 
 
Delivery: not reported 
 
Provider: not reported 
 
 
Abbreviations: COMP comparator; DSM-IV Diagnostic and Statistical Manual of Mental Disorders, 4th. Edition; EXP exposure; INT intervention; MDD major depressive disorder; SD standard deviation 
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Table C: Risk of bias assessment for RCTs 
 
 
Selective outcome reporting was not assessed for Klein at el., 2017 as this paper was reporting a secondary analysis
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Table D: Risk of bias assessment for single arm trials and observational studies 
 
 
Baldessarini 201053 Himei 200654 Johnson 201250 Huijbers 201634 Psaros 201451 
1. Was the research question 
or objective in this paper 
clearly stated? 
Yes - p.934,935 Yes - p.665,666 Yes - p.773 Yes - p.366 Yes - p.3 
2. Was the study population 
clearly specified and defined? 
Yes - p.935 Yes - p.666 Yes - p.773-774 Yes - p.367 Yes - p.3 
3. Was the participation rate 
of eligible persons at least 
50%? 
Not applicable - retrospective 
study 
 
 
 
 
Not applicable - retrospective 
study 
Can't determine - out of 96 
practices 71 agreed to 
participate (p.775), however 
of those patients prescribed 
long-term antidepressants 
only 2849 out of 15689 were 
reviewed and had forms 
submitted by their GP (p.775).  
Not applicable - study was two 
armed RCT of which one arm 
was relevant for review. 
Participation rate of eligible 
participants in whole RCT was 
49% (p.369). 
Yes - In total, 15 women were 
screened from July 2009 to 
June 2011, and 12 participants 
were enrolled. Three of the 
screened participants were 
ineligible for the study 
because of failure to establish 
Major Depressive Disorder 
(MDD) as the primary Axis I 
diagnosis (p.5). 
 
4. Were all the subjects 
selected or recruited from the 
same or similar populations 
(including the same time 
period)? Were inclusion and 
exclusion criteria for being in 
the study prespecified and 
applied uniformly to all 
participants? 
Can't determine - all patients 
included in the study had 
responded well to 
antidepressant treatment and 
were evaluated, treated, and 
followed at the Lucio Bini 
Mood Disorders Center 
affiliated with the University of 
Cagliari in Sardinia (p.935). 
Unclear over what period of 
time the patients were 
selected from.  
Yes - patients were treated 
during the previous five years 
and were treated in the 
outpatient clinic of one of two 
clinics. Unclear if there are 
important differences 
between the 2 clinics. 
However, inclusion criteria 
were detailed and would mean 
population was homogenous 
on important issues such as 
drug (paroxetine only), and 
that they had experienced a 
single episode of MDD (p.666). 
Yes - practices came from four 
of the  
community health and care 
partnerships (CHCPs) serving a 
highly urbanised population 
within the most deprived 
areas of Scotland with a high 
burden of disease and chronic 
conditions. These four CHCPs 
were interested in reviewing 
antidepressant prescribing and 
were high volume prescribers 
by defined daily doses (DDDs) 
per capita from the Prescribing 
and Information System for 
Scotland (PRISMS) (p.773-
774). 
 
Not applicable - study was two 
armed RCT of which one arm 
was relevant for review. 
Patients were recruited in 12 
secondary and tertiary 
psychiatric out-patient clinics 
across The Netherlands 
between September 2009 and 
January 2012. There were  
detailed inclusion and 
exclusion criteria (p.367). 
Yes - women were recruited 
from Massachusetts General 
Hospital (MGH) Center for 
Women's Mental Health in 
Boston, MA, or via a referral 
from another health care 
provider within the 
community, so there might be 
differences between these 
populations (p.3). However, 
there were detailed inclusion 
and exclusion criteria (p.3). 
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5. Was a sample size 
justification, power 
description, or variance and 
effect estimates provided? 
Not reported Not reported Yes - p.774 Not applicable - study was two 
armed RCT of which one arm 
was relevant for review. 
Sample size calculation for 
whole RCT was 280 in total (n 
= 140 per group) (p.4, Huijbers 
2012).  
Not reported - but following 
issues of sample size are 
mentioned in the paper:  
1. "Although significance 
testing could not be 
completed because of the 
small sample size, there were 
some apparent differences 
between those participants 
who did and did not relapse" 
(p.7). 
2. "Although the sample size 
and study design preclude us 
from drawing conclusions 
about this observed 
relationship, women with 
infertility or difficulty 
conceiving may be especially 
vulnerable to depressive 
recurrence and, as a result, 
may require more intensive 
monitoring and intervention" 
(p.7). 
3. "The nonrandomized design 
and small sample size do not 
allow for conclusions around 
the causality of treatment 
effects" (p.7). 
 
6. For the analyses in this 
paper, were the exposure(s) 
of interest measured prior to 
the outcome(s) being 
measured? 
Yes  Yes Not applicable (review and 
action taken with 
antidepressant took place at 
the same time) 
Yes Yes 
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7. Was the timeframe 
sufficient so that one could 
reasonably expect to see an 
association between exposure 
and outcome if it existed? 
Yes - mean follow up was 2.81 
years (SD 3.63). Follow up was 
every 2-4 months . Follow up 
was censored at 100 months 
(p.935) 
Yes - the groups are based on 
outcome 
No - limitations of study in 
discussion are:   
"The follow-up reviews by 
CHCP-1 demonstrated further 
prescribing reductions could 
be made. However, the 3-
month time period is likely too 
short to assess sustainability 
of reductions, especially as 
common mental health 
problems are relapsing and 
remitting in nature. Therefore, 
a 12-month follow-up period 
with reviews at 3, 6, and 12 
months would be more 
appropriate to assess long-
term sustainability of 
prescribing changes" (p.777). 
Yes - "Patients were asked and 
recommended to withdraw 
gradually from their 
antidepressants over a period 
of 5 weeks, starting after the 
seventh session of MBCT....... 
Adherence to the study 
protocol was defined as 
attending four or more MBCT 
sessions, as in previous studies  
and having fully discontinued 
mADM before the 6-month 
follow-up assessment (i.e. 
within 6 months after baseline 
and within approximately 3–4 
months after the last MBCT 
session"(p.367). 
Yes -  reports on 24 weeks of 
trial (p.5) 
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8. For exposures that can vary 
in amount or level, did the 
study examine different levels 
of the exposure as related to 
the outcome (e.g., categories 
of exposure, or exposure 
measured as continuous 
variable)? 
No - discontinuation was rapid 
(1-7 days) or gradual (≥2 
weeks) 
Not applicable - groups were 
based on outcome. In regard 
to tapering, the clinics only 
used one type of tapering 
strategy (a second one was 
later used to help patients in 
the discontinuation syndrome 
group successfully withdraw 
from paroxetine) 
Not applicable Yes - data for relevant study 
arm were provided for 
intention to treat population 
and per-protocol population 
(Adherence to the study 
protocol was defined as 
attending four or more MBCT 
sessions, as in previous 
studies, and having fully 
discontinued mADM before 
the 6-month follow-up 
assessment (i.e. within 6 
months after baseline and 
within approximately 3–4 
months after the last MBCT 
session) (p.367) 
 
Not applicable 
9. Were the exposure 
measures (independent 
variables) clearly defined, 
valid, reliable, and 
implemented consistently 
across all study participants? 
Yes - excluded those patients 
whose rate of discontinuation 
was uncertain (22.3% of 
potential antidepressant-
treated candidates) (p.935) 
Not applicable - groups were 
based on outcome. Outcomes 
of discontinuation syndrome 
or non-discontinuation 
syndrome were clearly 
defined.  
Yes Not applicable - study was two 
armed RCT of which one arm 
was relevant for review.  
Yes 
10. Was the exposure(s) 
assessed more than once over 
time? 
Not applicable Not applicable No - intervention was 1 GP 
review 
Not applicable 
 
Yes - For quality assurance, all 
sessions were audiotaped (p5) 
11. Were the outcome 
measures (dependent 
variables) clearly defined, 
valid, reliable, and 
implemented consistently 
across all study participants? 
Yes - first new episode of 
major depression or panic 
disorder that met DSM-IV 
diagnostic criteria at clinical 
assessment.(p.935) 
Not applicable - groups were 
based on outcome. 
Yes - GPs had standardised 
form with outcomes to 
complete (p.774) 
Yes - "The primary outcome 
measure was 
relapse/recurrence as 
measured with the SCID-I by 
trained research assistants 
every 3 
months during the follow-up 
period" (p.367). 
Yes - All assessments were 
performed by a research 
assistant or trained study 
clinicians. The research 
assistants were trained by the 
study psychologist on how to 
conduct and assess psychiatric 
interviews and questionnaires. 
Assessments were scripted, 
and training included mock 
interviews and 
assessments.(p.5) 
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12. Were the outcome 
assessors blinded to the 
exposure status of 
participants? 
Not reported Not reported Not reported No - "The research assistants 
conducting the assessments 
could not be masked to 
treatment group since they 
were also involved in the 
practical organisation of the 
trial" (p.367).  
 
Not reported 
13. Was loss to follow-up 
after baseline 20% or less? 
Not applicable - retrospective 
study.  
Not applicable - retrospective 
study.  
Not applicable No - over the course of the 
trial 28% were lost to follow-
up in the relevant study arm 
(p.369). 
Yes - all patients, including 3 
women who met study end 
point  completed all relevant 
sessions and assessments (p.6) 
 
14. Were key potential 
confounding variables 
measured and adjusted 
statistically for their impact 
on the relationship between 
exposure(s) and outcome(s)? 
Yes - effect of covariates 
examined (p.938). 
Not applicable - but statistical 
comparison, between those 
who experienced 
discontinuation syndrome and 
those that did not, of age, sex, 
maintenance and dosage and 
duration of treatment with 
paroxetine was made (p.667). 
Yes - Analysis by CHCP was 
performed (There was 
significant variation between 
CHCPs in patients continuing, 
stopping, reducing, increasing, 
or changing antidepressants 
(χ2 = 30.89, 12 df, P<0.005). 
This was attributable to CHCP-
1 having fewer patients 
change antidepressant than 
CHCPs 2, 3 & 4. There was no 
significant difference between 
CHCPs 2, 3 and 4) (p.776) 
 
Yes - depressive symptoms at 
baseline, and number of 
depressive episodes in the 
past (p.368) 
Yes - illness characteristics of 
relapses versus non relapsers 
were assessed (number of past 
episodes of depression, 
number of past failed 
attempts to discontinue 
antidepressants) (p.6). 
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Baldessarini 201053 Himei 200654 Johnson 201250 Huijbers 201634 Psaros 201451 
15. Any other forms of bias Can't determine - Conflicts of 
interest and funding were 
reported - 2 of the authors 
had research grants and 
consultantships with pharma. 
Research was funded through 
in part by NIH grant MH-
073579 to Drs. Tondo and 
Baldessarini; the Lucio Bini 
Private Donors Mood 
Disorders Research Fund to Dr. 
Tondo; and a grant from the 
Bruce J. Anderson Foundation 
and the McLean Private 
Donors Psychopharmacology 
Research Fund to Dr. 
Baldessarini (p.940). 
No - The authors have no 
conflicts of interest that are 
directly relevant to the 
content of this study and no 
sources of funding  were used 
to assist in conducting the 
study (p.672). 
No - The authors have 
declared no competing 
interests (p.778). 
No - The authors have 
declared no competing 
interests (p.366). 
Can't determine - Dr Psaros 
reports personal fees from 
Bracket Global. Dr Freeman 
reports grants from Eli Lilly, 
Forest, and GlaxoSmithKline; 
consulting with PamLab; an 
advisory board position with 
Takeda/Lundbeck and Otsuka; 
and medical editing for the 
Diagnostic and Statistical 
Manual of Mental Disorders 
nutritionals. Dr Safren and Ms 
Barsky have nothing to 
disclose. Dr Cohen reports 
grants from AstraZeneca 
Pharmaceuticals; Bayer 
HealthCare Pharmaceuticals; 
Bristol-Myers Squibb; 
Cephalon, Inc; Forest 
Laboratories, Inc; 
GlaxoSmithKline; National 
Institute on Aging; National 
Institute of Mental Health; 
Ortho-McNeil-Janssen; Pfizer, 
Inc; and Sunovion 
Pharmaceuticals, Inc. Dr Cohen 
also reports consultancy with 
Eli Lilly and Company (p.8) 
 
Options: Yes, no, can't determine, not reported, not applicable 
Abbreviations: DSM-IV Diagnostic and Statistical Manual of Mental Disorders, 4th. Edition; mADM maintenance antidepressant medication; MBCT mindfulness-based cognitive therapy; p. page number; 
SCID Structured Clinical Interview for DSM-IV; SD standard deviation 
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Table E: Studies reporting relapse/recurrence within six months of discontinuation 
 
Study (design) 
Definition of 
relapse/recurrence 
Intervention 
(relapse/recurrence 
rate) 
Comparator 
(relapse/recurrence 
rate) 
Results 
Depression (exclusion or non-reporting of anxiety comorbidities) 
Psaros 201451 
(Single arm) 
 
Criteria for a current 
depressive episode 
according to the MINI, or 
AD treatment re-
initiation 
CBT + taper 
(2/12 = 17%) 
 
n/a 2 participants relapsed 5 
weeks and 10 week after 
completing AD taper; 1 
participant reinitiated AD 
treatment 1 week after 
completing AD taper 
although they did not 
meet full criteria for a 
major depressive episode  
Himei 200654 
(Retrospective cohort) 
 
DSM-IV criteria 
 
41 patients with discontinuation syndrome after either abrupt (n=27) or gradual  
(n=14) withdrawal of paroxetine (10mg reduction every 2 weeks) 
Subsequently, 36/41 re-administered paroxetine and tapered off by 5mg every 2–
4 weeks. 5/41 required change of medication, as unable to tolerate adverse 
effects of paroxetine. 0/41 relapsed 4 and 8 weeks after paroxetine stopped. 
Depression and/or anxiety disorders 
Baldessarini 201053 
(Retrospective cohort) 
 
DSM-IV-TR criteria 
Gradual discontinuation - 
≥ 2 weeks 
 
Median time to 
recurrence (months): 
MDD: 7.60  
Panic disorder: 13.2  
Rapid discontinuation –  
1-7 days 
 
Median time to 
recurrence (months): 
MDD: 3.17 
Panic disorder: 4.23 
Ratio of occurrence 
latency (gradual/rapid): 
 
MDD: 2.40 
Panic disorder: 3.1 
 
Abbreviations: AD antidepressant; CBT cognitive behavioural therapy; DSM-IV Diagnostic and Statistical Manual of Mental 
Disorders, 4th. Edition; DSM-IV-TR Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision; MDD major 
depressive disorder; MINI The Mini-International Neuropsychiatric Interview; n/a not applicable 
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Table F: Studies reporting recurrence more than six months after discontinuation 
 
Study (design) 
Definition of 
recurrence 
Timepoint – 
from baseline  
Intervention 
(recurrence rate) 
Comparator 
(recurrence rate) 
Risk ratio 
(95% CI) 
Depression (exclusion or non-reporting of anxiety comorbidities) 
Huijbers 201634  
(Single arm from RCT)1 
 
DSM-IV criteria for 
depressive episode 
15 months 
 
MBCT-TS 
(69/128 = 54%) 
 
n/a n/a 
Depression and/or anxiety disorders 
Eveleigh 201527 
(RCT) 2 
 
Severity of symptoms 
on BSI-53 and CESD 
After 1 year Letter to PCP 
with 
recommendation 
+ tapering advice  
(18/70 = 26%) 
 
Usual care 
(10/76 = 13%) 
 
1.95 (0.97, 3.94; 1 
study) 
 
Fava 199415 
(RCT)3 
 
RDC defined episode of 
major depression 
2 years; 4 years;  
6 years 
CBT + taper 
(3/20 = 15%; 
7/20 = 35%; 
10/20 = 50%) 
 
CM + taper 
(7/20 = 35%; 
14/20 = 70%; 
15/20 = 75%) 
 
2 years:  
0.34 (0.18, 0.67; I2 
= 0%; 2 studies) 
 
6 years:  
0.55 (0.37, 0.82; I2 
= 11%; 2 studies) 
 
Fava 199832 
(RCT)4 
 
RDC defined episode of 
major depression 
2 years; 6 years CBT + taper 
(5/20 = 25%; 
8/20 = 40%) 
 
CM + taper 
(6/20 = 80%; 
18/20 = 90%) 
Kuyken 200816  
(RCT)2 
 
DSM–IV criteria for 
major depressive 
disorder 
15 months MBCT-TS 
(29/61 = 48%) 
m-ADM 
(37/62 = 60%) 
 
≥15months: 
 
0.90 (0.75, 1.07; I2 
= 0%; 2 studies) 
 
Kuyken 201517 
(RCT)2 
 
SCID-LIFE score of 5 for 
2 consecutive weeks at 
any time 
24 months  MBCT-TS 
(94/212 = 44%) 
 
 
m-ADM 
(100/212 = 47%) 
 
1 RCT but only 1 arm is relevant for this review, ITT analysis; 2 ITT analysis; 3 complete case analysis (95% and 91% of those 
randomised to the intervention and comparator arms respectively); 4 complete case analysis (87% and 91% of those randomised 
to the intervention and comparator arms respectively) 
Abbreviations: BSI-53 Brief Symptom Inventory; CESD Centre for Epidemiological Studies Depression Scale; CM clinical 
management; CBT cognitive behavioural therapy; DSM-IV Diagnostic and Statistical Manual of Mental Disorders, 4th. Edition; ITT 
intention to treat; m-ADM maintenance antidepressant medication; MBCT-TS Mindfulness based cognitive therapy with support 
to taper; n/a not applicable; PCP Primary Care Provider; RDC Research Diagnostic Criteria; SCID-LIFE Structured Clinical Interview 
for DSM-IV - Longitudinal Interval Follow-up Evaluation 
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Table G: Studies reporting Quality of Life 
 
Study (design) Measure 
(Timepoints) 
 
Intervention 
 
Comparator 
 
Mean difference 
(95% CI) 
Depression (exclusion or non-reporting of anxiety comorbidities) 
Psaros 201451 
(Single arm) 
 QLESQ 
Baseline, time of 
relapse, end of 
acute phase, at 
24 weeks from 
baseline 
CBT + taper  n/a 
(see text for results) 
Depression and/or anxiety disorders 
Eveleigh 
201527 
(RCT)1 
QALY  
(calculated using  
EQ-5D)  
12 months 
Letter to PCP with 
recommendation + 
tapering advice  
 
Mean: 0.70; SE: 
0.03; SD: 0.25 N: 
70 
Usual care 
 
Mean: 0.72; SE: 
0.03; SD: 0.26; N: 
76 
-0.02 (-0.10, 0.06; 1 study) 
Kuyken 200816 
(RCT)2 
 WHOQOL-BREF 
(physical; 
psychological; 
social; 
environmental) 
 
1 month post 
treatment, 15 
months from 
baseline 
MBCT-TS 
 
Physical  
1 M: mean:24.08; 
SD: 5.75; N:60  
15 M: mean: 
29.37; SD: 5.28; N: 
60 
 
Psychological 
1 M: mean: 18.88; 
SD:3.97; N: 60 
15 M: mean: 
18.61; SD: 3.79; N: 
60 
 
Social  
1 M: mean: 10.09; 
SD: 2.15; N: 60 
15 M: mean: 10; 
SD: 2.27; N: 60 
 
 
m-ADM 
 
Physical  
1 M: mean: 22.86; 
SD: 5.78; N: 59  
15 M: mean: 
22.93; SD: 6.88; N: 
59 
 
Psychological  
1 M: mean: 17.47; 
SD:4.82; N: 59 
15 M: mean: 
17.36; SD: 5.58; N: 
59 
 
Social  
1 M: mean: 9.08; 
SD: 2.74; N: 59 
15 M: mean: 9.66 ; 
SD: 3.06; N: 59 
 
1 month post treatment 
Physical:  
0.20 (-0.68, 1.08; I2 = 17%; 
2 studies) 
 
Psychological:  
0.87 (0.33, 1.40; I2 = 0%; 2 
studies) 
 
Social:  
0.68 (0.15, 1.22; I2 = 0%; 2 
studies) 
 
 
≥12 months from 
baseline 
Physical:  
-0.12 (-1.58, 1.34; I2 = 
48%; 2 studies) 
 
Psychological:  
0.36 (-0.75, 1.47; I2 = 45%; 
2 studies) 
 
Social: 
-0.01 (-0.59, 0.58; I2 = 0%; 
2 studies) 
  
Kuyken 201517 
(RCT)3 
EQ-5D,  
WHOQOL-BREF 
(Q1 overall 
perception of 
health;  
Q2 overall 
perception of 
health; 
 physical; 
psychological; 
social; 
environment) 
MBCT-TS 
 
Physical 
1 M: mean: 14.3; 
SD: 3.3; N: 174 
12 M: mean: 14.1; 
SD:3.4; N: 166 
 
Psychological 
1 M: mean: 13.4; 
SD:2.6; N: 174 
12 M: mean: 13.3; 
m-ADM 
 
Physical 
1 M: mean: 14.3; 
SD: 3.0; N: 173 
12 M: mean: 14.7; 
SD: 3.3; N: 157 
 
Psychological  
1 M: mean: 12.6; 
SD; 2.8; N: 173 
12 M: mean: 13.3; 
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1 month post 
treatment, 9, 12, 
18 and 24 
months from 
baseline 
SD: 2.9; N: 166 
 
Social 
1 M: mean: 13.8; 
SD:2.9; N: 174 
12 M: mean: 13.7; 
SD: 3.3; N: 169 
 
 
SD: 2.7; N: 157 
 
Social 
1 M: mean: 13.3 ; 
SD: 3.4; N: 173 
12 M: mean: 13.9; 
SD: 3.5; N: 167 
 
 
1 ITT analysis;  2 Complete case analysis (1 month post treatment and at 15 months, 98% and 95% of those randomised to the 
intervention and comparator arms respectively)  3 Complete case analysis (1 month post treatment 82% of those randomised to 
the intervention and comparator arms, 24 months, 79%  and 80% of those randomised to the intervention and comparator arms 
respectively) 
Abbreviations: EQ-5D European Quality of Life five dimensions questionnaire; M months; PCP Primary Care Provider; QALY Quality 
Adjusted Life Years; QLESQ Quality of Life Satisfaction; SD standard deviation; SE standard error; WHOQOL-BREF World Health 
Organization Quality of Life instrument 
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Table H: Studies reporting reduction in antidepressant dosage, usage or combination 
 
Study (design) Timepoint – 
from baseline 
Intervention 
(reduction rate) 
Comparator 
(reduction rate) 
Other results 
Depression (exclusion or non-reporting of anxiety comorbidities) 
Klein 201742 
(RCT)1 
6 months CBT + taper 
(Minimum 50% 
reduction of 
ADM use: 
16/85 = 19%) 
 
m-ADM (n/a) n/a 
Huijbers 201634 
(Single arm from RCT)2 
Not reported MBCT-TS 
(Reduction in 
ADM: 17/128 = 
13%) 
 
n/a n/a 
Depression and/or anxiety disorders 
Kuyken 201517 
(RCT) 3 
24 months MBCT-TS 
(Reduction in 
ADM 
dose:29/176 = 
16%) 
 
m-ADM (n/a)  
Johnson 201250 
(single arm) 
Post intervention Guided PCP 
review 
(Reduced dose: 
366/2849 = 
12.8%) 
 
n/a 9.5% (95% CI = 
9.1% to 9.8% 
P<0.001) 
reduction in mean 
PDD, expressed as 
DDDs. Estimated 
8.1% (£23 320 per 
annum) reduction 
in antidepressant 
prescribing costs.  
 
1 3 arm RCT, but only 2 arms are relevant for this review, ITT analysis; 2 RCT but only 1 arm is relevant for this review; ITT analysis; 3 
per protocol analysis (completed 4 sessions of MBCT, 83% of those randomised to intervention arm) 
Abbreviations: ADM antidepressant medication; CBT cognitive behavioural therapy; DDD defined daily doses; m-ADM 
maintenance antidepressant medication; MBCT-TS Mindfulness based cognitive therapy with support to taper; n/a not applicable; 
PCP Primary Care Provider, PDD prescribed daily dose. 
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